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RNA degradation plays a fundamental role in maintaining cellular homeostasis, 
along with being a part of normal regulatory mechanisms, whether it occurs as a 
surveillance mechanism eliminating aberrant mRNAs or during RNA processing to 
generate mature transcripts. 3’-5’ exoribonucleases are essential mediators of RNA 
decay pathways, and one such evolutionarily conserved enzyme is polynucleotide 
phosphorylase (PNPase). The human homologue of this fascinating enzymatic protein 
(hPNPaseold-35) was cloned a decade ago in the context of terminal differentiation and 
senescence through a novel ‘overlapping pathway screening’ approach. Since then, 
significant insights have been garnered about this exoribonuclease and its repertoire of 
	  
	  
xix	  
expanding functions. hPNPaseold-35 has progressed a long way from being just a 3’-5’ 
exoribonuclease to a functionally relevant molecule implicated in a multitude of diverse 
and important biological effects. hPNPaseold-35 plays central roles in diverse 
physiological processes including growth inhibition, senescence, mtRNA import, 
mitochondrial homeostasis, and RNA degradation, all while primarily being localized in 
the mitochondrial IMS (inter membrane space). hPNPaseold-35 also holds immense 
promise as a therapeutic agent due to its ability to degrade specific miRNA (miR-221) 
and mRNA (c-myc) species, and this property can be exploited in treating malignancies 
that are characterized by upregulation of harmful miRNA or mRNA molecules. But apart 
from these two targets, little is known about any other targets hPNPaseold-35 may 
degrade. Thus, the primary objective of this dissertation research was to identify targets 
other than c-myc or miR-221 that hPNPaseold-35 could directly degrade to discover 
newer and biologically relevant therapeutic targets for the treatment of hPNPaseold-35 –
associated disease states. In order to do this we performed extensive microarray 
analyses following hPNPaseold-35 overexpression and depletion in mammalian cell lines, 
and were able to identify transcripts that could be potentially regulated by hPNPaseold-35 
directly or indirectly. Apart from this we also analyzed the 3’UTR of c-myc in order to 
identify any specific sequence or secondary structural elements necessary for 
hPNPaseold-35 mediated degradation. Lastly, we identified certain residues in 
hPNPaseold-35 that have been under positive natural selection through evolution.      
 
 	  	  	  	  	   1	  
 
 
 
 
 
 
CHAPTER ONE 
 
 
 
INTRODUCTION 
 
 
Part of the work presented in this chapter has been published in Advances in Cancer 
Research 119:161-90 (2013).  
 
1.1 RNA degradation pathways  
Post-transcriptional control of gene expression occurs at multiple steps that 
include mRNA processing, its export from the nucleus to cytoplasm, mRNA localization, 
mRNA stability, translational regulation and finally mRNA decay [1]. A number of 
evolutionarily conserved trans-acting regulatory factors have been identified over the 
past years that are involved in each of these steps [2,3]. Previously, RNA degradation 
was thought to be a random process, but studies over the past few years have proved 
quite the contrary. It is a well-controlled process involving the interplay of a number of 
proteins working together and contributing to the maintenance of cellular homeostasis 
[4]. Two major pathways have been identified for eukaryotic mRNA turnover, 
deadenylation-dependent decay and deadenylation-independent decay [5-7]. 
Deadenylation-dependent decay is usually triggered by the presence of certain cis-
elements in the mRNA sequence such as AU-rich elements in the 3’UTR and instability 
elements in the coding region [8,9]. The first step in this process is the shortening of the 
	  	   2	  
poly(A) tail or deadenylation, which is brought about by certain deadenylases like the 
Ccr4/Pop2/NOT complex, Pan2/Pan3 or PARN [poly(A) ribonuclease]. Following this 
process, the mRNA can undergo 3’-5’ decay by the exosome, which is a complex of 3’-
5’ exoribonucleases or PNPase (a phosphorolytic 3’-5’ exoribonuclease), with the 
residual cap structure being hydrolysed by the scavenger enzyme DcpS or 5’-3’ 
exonucleolytic digestion by an exonuclease Xrn1p after decapping by the Dcp1/Dcp2 
enzyme complex [8,10]. Deadenylation-independent decay, mostly consisting of RNA 
surveillance mechanisms, may occur when there is a premature stop codon in the 
mRNA sequence (Nonsense-mediated decay or NMD) in which case 5’-3’ digestion 
occurs after removal of the cap structure by the same enzymes discussed earlier [7,11]. 
In the event of an absence of a termination codon (Nonstop decay or NSD), the 
aberrant mRNA is recognized and degraded in a 3’-5’ manner by the exosome. When 
there is a stall in translation elongation (No-go decay or NGD), cleavage occurs at the 
stall site by an endonuclease (IME1, PMR1 or RNase MRP) after which the fragments 
are digested by the 3’ and 5’ exoribonucleases [11]. These processes are summarized 
in Fig. 1.1. 
	  	   3	  
 
 
1.2 Exoribonucleases 
Ribonucleases (RNases) are the main players involved in RNA metabolism, 
performing important roles in RNA maturation, RNA end-turnover and in the degradation 
of aberrant RNAs or species no longer required by the cell [12]. Based on their 
degradative properties, they are classified into exo- and endo-ribonucleases, with 
exoribonucleases being further classified into 5’-3’ and 3’-5’ exoribonucleases 
depending on the direction of degradation [13]. Eukaryotes possess both these classes 
of enzymes whereas prokaryotes like E. coli lack the 5’-3’ exoribonuclease activity. 
Extensive sequence homology studies have culminated in the various exoribonucleases 
in all kingdoms to be grouped into the following superfamilies (with representative 
Fig. 1.1. RNA decay mechanisms. A diagrammatic representation of various RNA 
degradation pathways. Refer to text for details. 
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examples from E.coli and some of their eukaryotic homologues): the RBN (RNase BN) 
family present only in eubacteria, the RNR (RNase II, RNase R, Rrp44, Dss I, Ssd I), 
DEDD (RNase D, RNase T, oligoribonuclease, Rrp6, Pan2, Rex1-4),and PDX (Rnase 
PH, PNPase, Rrp41-43, 45, 46, Mtr3) families present in bacteria, archaea and 
eukaryotes, the RRP4 (Rrp4, 40, Csl4) family present in archaea and eukaryotes and 
lastly the 5PX (Xrn1, Rat1) family present only in eukaryotes [14,15]. RNA degradation 
by most exoribonucleases occurs via hydrolytic cleavage of the 3’ phosphodiester bond 
to generate nucleotide monophosphates, but certain members like PNPase and RNase 
PH do so through a phosphorolytic mechanism that utilizes inorganic phosphate to 
generate nucleotide diphosphates [4].       
1.3 PNPase  
Polynucleotide phosphorylase (PNPase) is an evolutionarily conserved 
phosphorolytic 3’-5’ processive exoribonuclease that is present in all phyla extending 
from bacteria, plants, worms and flies, to mice and humans, although it is absent in 
fungi, trypanosomes and Archaea [13]. Studies in E.coli have shown that in the 
presence of high inorganic phosphate (Pi), this enzyme acts exclusively as an 
exoribonuclease, whereas in the event of low Pi, it acts as a polymerase resulting in the 
elongation of the poly(A) tail by adding nucleotides and generating Pi. PNPase was 
discovered by Severo Ochoa and Marianne Grunberg-­‐Manago in 1955 and Ochoa 
received the Nobel Prize in 1959 for discovering its polymerizing activity [4,16].  The 
human homologue of PNPase (hPNPaseold-35) was first identified as a gene that was 
upregulated in terminally differentiated human melanoma cells and senescent progeroid 
	  	   5	  
fibroblasts in an ‘overlapping pathway screen’ to identify differentially regulated genes in 
the context of terminal differentiation and senescence (Fig. 1.2) [17].  
 
1.3.1 PNPase structure 
PNPase from all diverse species share a classical domain structure that contains 
a catalytic PDX domain characteristic of all PDX family members [13,18]. Almost all 
PNPases are composed of five conserved structural motifs; the amino-terminal domain 
is composed of 2 RNase PH domains, an α-helical domain that separates the RNase 
Fig. 1.2. Identification of human PNPase. Schematic representation of the 
overlapping pathway screen that aided in the identification of transcripts 
upregulated in the processes of terminal differentiation and senescence. 
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PH domains, and 2 carboxy-terminal RNA-binding domains KH (K-homology) and S1 
[13,18-20] (Fig. 1.3).  
 
In plants, PNPase is translocated to the chloroplast stroma or mitochondrial 
matrix by an N-terminal chloroplast-transit peptide (cTP) or a mitochondrial-targeting 
sequence (MTS), respectively [21]. Human PNPase (hPNPaseold-35), a 783 amino acid 
long ~86 kDa protein, also contains an N-terminal MTS that allows its primary location in 
the cell to be the mitochondria, where it assembles into a homotrimer or a dimer of two 
homotrimers [22,23]. PNPase from the bacterium Streptomyces antibioticus was the 
first to be crystallized; it was observed that it forms a homotrimeric doughnut shaped 
structure with a central channel formed by the 6 RNase PH domains containing the 
catalytic sites and through which a single-stranded RNA molecule can enter [20,24]. 
Extensive deletion and mutation studies have been done in the past decade to 
Fig. 1.3. Domain organization of PNPases from different species. PNPases from 
humans, plants and bacteria showing the presence of two conserved catalytic 
RNasePH domains and two RNA binding domains KH and S1.	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understand the structural specificities of the phosphorolytic and RNA-binding properties 
of PNPase. The catalytic activity of the bacterial PNPase resides mainly in the second 
RNase PH domain, which also seems to possess RNA binding ability as demonstrated 
by a G454D mutation, but both domains are required for proper enzymatic activity [25]. 
In bacteria, deletion of the KH or S1 domain reduces the specific activity of the enzyme 
by ~19- or ~50-fold, respectively, whereas deleting both domains reduces the enzymatic 
activity to ~1% [26]. X-ray crystallography studies using E.coli full-length and KH/S1 
truncated PNPase further elucidated that the KH and S1 domains are important for 
proper trimer formation apart from RNA binding along with certain conserved residues in 
the first RNase PH domain that are important for proper RNA binding and processive 
degradation [27]. In case of plants, chloroplast PNPase exists as a homo-multimer [28] 
and both its RNase PH domains possess phosphorolytic and polymerizing activities 
[21]. Mutation analysis of human PNPase showed that it possesses similar 
phosphorolytic properties to its homologues in different species, with both the RNase 
PH domains possessing equal enzymatic activity, and the presence of either one of 
them being sufficient for complete enzymatic activity as shown in our studies [29]. 
However, there are some differences in its RNA-binding affinities compared to other 
species of PNPases [30]. Also, human PNPase still retains enzymatic activity after 
deletion of both the KH and S1 domains in contrast to its bacterial homologue, which 
further strengthens the observation that the RNase PH domains may also play a role in 
RNA binding after all [29].  
    More recent advances in understanding the structural evolution of this interesting 
exoribonuclease come from the successful crystallization of an S1-domain truncated 
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human PNPase [31]. This study reveals a slight difference between the bacterial and 
human PNPases, in that the S1 domain was found to be dispensable for RNA binding 
and the 3 KH domains formed a pore on top of the homotrimer (formed by the 6 RNase 
PH domains), which in turn is solely responsible for binding RNA through its conserved 
GXXG motif [31]. Although this is an exciting finding, it stands in contrast to previously 
published reports as mentioned earlier, that the RNase PH domains also possess RNA 
binding ability [29]. Future studies crystallizing the full length and maybe a KH domain 
truncated human PNPase may provide useful insights into the workings of this intriguing 
protein.     
1.3.2 PNPase, degradosome, exosome  
Apart from existing as an individual entity in the cytoplasm, PNPase is also found 
as part of a multiprotein complex associated with endonuclease RNase E, the DEAD-
box helicase RhlB and enolase, a glycolytic enzyme in bacteria [32-36]. This structure is 
called the degradosome and contains approximately 20% of the total PNPase present in 
the bacterial cell [37]. Yeast contains a similar multiprotein complex consisting of 
exoribonucleases called the exosome present in the nucleus and the cytoplasm, from 
which PNPase is absent [38,39]. The yeast exosome is made up of 8 exoribonucleases 
(Rrp6p, Rrp41-46p and Mtr3p) with some of them sharing homology with bacterial 
RNase PH and 3 RNA binding subunits (Rrp4p, Rrp40p and Csl4p) [40]. All of the yeast 
exosome subunits have human homologues, except Rrp43p and Mtr3p [19,41]. There is 
high structural homology between the eukaryotic exosome and homotrimeric PNPase, 
both looking like ring-shaped structures with a central catalytic core channel through 
which the RNA molecule enters for degradation [24], although recent studies have 
	  	   9	  
shown that human PNPase possesses a KH pore versus a S1 pore in exosomes that 
facilitates RNA-binding [31].   
1.4 Identification and regulation of hPNPaseold-35 expression 
Human PNPase is encoded by the gene PNPT1 mapping to chromosome 2p15-
2p16.1, consisting of 28 exons and spanning ~60 kb on the reverse strand [42]. It was 
first identified as a gene that was upregulated in senescent progeroid fibroblasts and 
terminally differentiated HO-1 human melanoma cells in a quest to recognize molecular 
mediators controlling cellular senescence and differentiation that would aid in 
improvement of cancer therapy [17]. Human melanoma is a well-established model for 
studying differentiation therapy of cancer and terminal differentiation, which can be 
induced by combined treatment with recombinant human fibroblast interferon (IFN)-β 
and protein kinase C activator mezerein (MEZ), resulting in similar phenotypic 
characteristics as cellular senescence. These findings formed the basis for a screening 
strategy intended to identify overlapping gene expression changes associated with both 
terminal differentiation and senescence (Fig. 2). cDNA from terminally differentiated 
HO-1 cells was used to generate a differentiation-induction subtraction hybridization 
(DISH) library, which was screened with a probe generated from the mRNA of 
senescent progeroid fibroblasts [17,43]. Of the 75 genes identified through this 
screening approach designated old-1 to old-75, old-35 was one of the identified cDNAs 
that showed an elevated expression associated with both terminal differentiation and 
senescence [17]. old-35 exhibited substantial sequence homology to PNPase from 
other species and was thus identified as human polynucleotide phosphorylase or 
hPNPaseold-35. hPNPaseold-35 is expressed in all primary tissues [17] and a PNPT1 
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knockout mouse is embryonic lethal, indicating its importance in early mammalian 
development [44]. 
    Bacterial PNPase has been shown to autocontrol its own expression at the post-
transcriptional level by binding and degrading part of a stem-loop structure in its own 
mRNA 5’-leader sequence cleaved by RNase III, subsequently resulting in mRNA 
instability and reduced expression [45]. On the other hand, not much is known about the 
transcriptional or post-transcriptional regulation of hPNPaseold-35, except that it is 
induced by type I interferons (IFN-α and -β) at the transcription level in both normal and 
cancer cells [42]. Since type I interferons are cytokines secreted by cells in response to 
viral infections, it could be speculated that hPNPaseold-35 may play a role in the cell’s 
antiviral response through its RNA processing function. Induction of hPNPaseold-35 
mRNA, which has a half-life of ~6h [42], was evident even with 1 U/ml of IFN-β and as 
early as 3 hrs in HO-1 cells (2000 U/ml IFN-β), demonstrating that it is an early IFN 
response gene [17] (Fig. 1.4).  
 
 
 
	  	   11	  
 
 
IFN-γ and TNF-α treatment resulted in minimal or no induction, whereas poly(I)/poly(C), 
which induces IFN-α and -β, also stimulated hPNPaseold-35 expression [17]. Promoter 
characterization experiments and sequence analysis resulted in the identification of an 
IFN-stimulated response element (ISRE) in the hPNPaseold-35 promoter, to which the 
ISGF3 complex shows increased binding upon IFN-β treatment [42]. Mutating this site 
abrogated promoter induction, demonstrating that IFN-β is a transcriptional activator of 
hPNPaseold-35 whose activation depends on the JAK/STAT signal transduction pathways 
[42]. In silico analysis of the hPNPaseold-35 promoter has highlighted several additional 
transcription factor binding sites, but at present any connection of these regulatory 
elements to physiological conditions relating to hPNPaseold-35 expression remains to be 
determined [46]. In any case, it would be relevant to determine if there are other 
regulatory factors controlling hPNPaseold-35 expression levels and future endeavors 
towards achieving this goal are required to better understand hPNPaseold-35 functions.   
Fig. 1.4. Regulation of hPNPaseold-35 expression by IFN-β. (A) Induction of 
hPNPaseold-35 mRNA by IFN-β post 24 hours in melanoma cell lines. (B) IFN-β induces 
hPNPaseold-35 protein resulting in downregulation of c-myc post 48hours in melanoma 
cell lines.	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1.5 Subcellular Localization of hPNPaseold-35 
Human PNPase possesses a mitochondrial-targeting signal (MTS) at its amino 
terminus. Immunofluorescence and cell fractionation studies demonstrated that 
endogenous and C-terminal myc-tagged hPNPaseold-35 localizes exclusively to the 
mitochondria [22]. It was expected that the location was obviously mitochondrial matrix, 
where an enzyme like hPNPaseold-35 was predicted to perform mitochondrial RNA 
processing analogous to its bacterial and chloroplast counterparts. However, 
subsequent research involving subfractionation studies, protease protection assays and 
carbonate extraction experiments proved that hPNPaseold-35 is actually a peripheral 
inner membrane (IM) - bound protein located in the mitochondrial inter membrane 
space (IMS) [47] and is imported to this location via an i-AAA protease Yme1-dependent 
mechanism [23]. hPNPaseold-35 first enters through the TOM complex at the outer 
mitochondrial membrane, and this is followed by its N-terminus extending through the 
TIM23 complex at the inner mitochondrial membrane into the matrix, enabling its 
cleavage by the matrix-processing peptidase (MPP). Yme1 localized at the inner 
membrane first facilitates release of the N-terminus into the IMS followed by pulling the 
C-terminus of hPNPaseold-35 across the TOM complex into the IMS [23]. While these 
studies are quite convincing, the topic of hPNPaseold-35 subcellular localization has been 
controversial, as our studies involving ectopic overexpression of hPNPaseold-35 have 
shown that it localizes to both the mitochondria and cytoplasm. In our overexpression 
studies, N-terminal GFP-tagged hPNPaseold-35 was found to localize to the cytoplasm 
[17], which is consistent with the findings of Chen et al [18].  This observation might be 
due to blockage of the N-terminal MTS, although we did not see an effect of this on the 
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growth inhibitory effects of hPNPaseold-35. C-terminal HA-tagged hPNPaseold-35 on the 
other hand localizes both in the mitochondria and cytoplasm as documented in our 
studies. There may be shuttling mechanisms that facilitate the transport of hPNPaseold-
35 from the mitochondrial IMS to the cytoplasm, like the one suggested by Chen et al. 
where hPNPaseold-35 migrated to the cytoplasm after mitochondrial outer membrane 
(OM) permeabilization [47], thus allowing it to degrade certain mRNA and miRNA 
species as reported previously in our studies [48,49]. Conversely physiological 
conditions allowing OM permeabilization or RNA import pathways could also allow RNA 
substrates to enter the IMS and subsequently get processed by hPNPaseold-35 [44,50]. 
Recently, hPNPaseold-35 has also been found in the nucleus of breast cancer cells 
exposed to ionizing radiation where it interacts with nuclear EGFR [51]. Further studies 
are required to establish whether this is a global or cell line and condition specific 
phenomena. Based on all this information it would be safe to say hPNPaseold-35 may 
have distinct roles based on its specific localization in distinct cellular compartments.  
1.6 Functions of hPNPaseold-35 
1.6.1 hPNPaseold-35, growth inhibition, senescence and RNA degradation 
As mentioned earlier, hPNPaseold-35 was first identified as a gene that was 
upregulated in senescent progeroid fibroblasts and terminally differentiated HO-1 
human melanoma cells [17]. Both senescence and terminal differentiation share certain 
common characteristics like irreversible growth arrest notably occurring in the G1 phase 
of the cell cycle, with inhibition of both DNA synthesis and telomerase activity [52-54]. 
To elucidate the functional link between a 3’-5’ exoribonuclease like hPNPaseold-35 and 
phenomena like senescence and terminal differentiation, replication-incompetent 
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adenoviral mediated hPNPaseold-35-overexpression (Ad.hPNPaseold-35) studies were 
performed [48]. (Fig. 1.5) 
 
 
It was observed that slow and sustained overexpression of hPNPaseold-35 results in 
inhibition of growth of multiple cells types and induces a senescent-like phenotype in 
HO-1 human melanoma cells and normal human melanocytes, ultimately resulting in 
apoptosis [29,48]. The morphological features evident after about 5 days of adenoviral 
infection in HO-1 cells are very similar to terminally differentiated HO-1 cells treated with 
IFN-β and mezerein for the same period of time, which is accompanied by inhibition of 
telomerase activity [48]. In separate studies, normal human melanocytes stained 
positive for SA-β-gal, a well known biochemical marker for senescence, and 
morphologically resembled cells entering a senescent stage by becoming large and 
flattened after Ad.hPNPaseold-35 infection [48]. This senescence-like phenotype could 
also be mediated by adenoviral overexpression of either of the 2 RNase PH domains of 
Fig. 1.5. Adenoviral-mediated hPNPaseold-35 overexpression causes inhibition 
of cellular proliferation of HO-1 cells. (A)	  HO-1 cells were infected with Advec or 
Ad.hPNPaseold-35 at an m.o.i. of  5000vp/cell. 6 hrs later, the cells were trypsinized, 
counted and 1000 cells were plated per 6-cm dish (in triplicate). Colony numbers 
were determined after 3 weeks. (B) Graphical representation of colony numbers. 
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hPNPaseold-35 alone, which was confirmed by deletion studies of the full-length protein 
[29]. Cell cycle analysis of different cell lines infected with Ad.hPNPaseold-35 showed an 
initial G1/S or G2/M arrest with inhibition of DNA synthesis followed by induction of 
apoptosis [48,55]. This was accompanied by gene expression changes resembling 
those occurring during terminal differentiation and senescence, including upregulation of 
CDKI p27Kip1 levels and decreases in CDKI p21CIP1/WAF-1/MDA-6 levels, both of which play 
significant roles in cell cycle arrest [48]. On the other hand, rapid overexpression of 
hPNPaseold-35 rapidly promotes apoptosis without any cell-cycle changes, implying that 
multiple intracellular targets and signaling pathways are involved in hPNPaseold-35-
mediated inhibition of cell-cycle progression and apoptosis.  
1.6.2 Molecular mechanisms of growth inhibition and senescence: Interestingly, 
some light was shed on one of the molecular mechanisms of hPNPaseold-35-induced 
growth-inhibition and senescence when it was observed that Ad.hPNPaseold-35 
overexpression could downregulate c-myc mRNA and protein expression [48]. 
Interestingly, its expression is downregulated during both terminal differentiation of HO-
1 melanoma cells and senescence. Myc is an important transcription factor that 
regulates numerous physiological processes like cellular growth and proliferation, 
metabolism and apoptosis [56]. It is one of the key mediators that play a role in 
transition of cells from the G1 to S phase of the cell cycle and is known to control p27Kip1 
expression by multiple mechanisms. Rescue experiments involving ectopic 
overexpression of c-myc CDS (coding sequence) significantly protected HO-1 cells from 
Ad.hPNPaseold-35 mediated cell death, confirming that one mechanism by which 
Ad.hPNPaseold-35 causes growth inhibition is by downregulating c-myc expression (Fig. 
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5) [48]. However, since c-myc overexpression provided only partial protection from 
Ad.hPNPaseold-35-mediated cell death, there might be other pathways involving genes 
that may be direct targets of hPNPaseold-35 degradation, which is an interesting avenue 
of investigation we are currently pursuing. Interestingly, in a recent study breast cancer 
cells resistant to ionizing radiation had higher levels of c-myc mRNA. This was 
attributed to an inactive form of hPNPase which was phosphorylated at S776 in the 
nucleus by nEGFR-regulated DNAPK, resulting in its inability to degrade c-myc mRNA 
[51]. 
    The mechanism by which hPNPaseold-35 mediates apoptosis has also been 
identified and is attributed to its ability to activate double-stranded RNA (dsRNA)-
dependent protein kinase (PKR) and phosphorylation of eIF-2α. Activation of PKR 
results in induction of GADD153 and a decrease in the levels of the anti-apoptotic 
protein Bcl-xL, ultimately culminating in apoptosis [57].  
    Inhibition of growth by IFN-β is also characterized by downregulation of c-myc 
expression, which it is known to regulate post-transcriptionally [58,59]. hPNPaseold-35 
induction following IFN-β treatment has also been shown to downregulate c-myc mRNA 
and miR-221 levels, implicating its important role in IFN-β-mediated growth inhibition 
[49,60]. The role of hPNPaseold-35 in IFN-β-mediated growth inhibition is further 
strengthened by the finding that transient or stable knockdown of hPNPaseold-35 in 
melanoma cells makes them resistant to IFN-β-mediated cell death [60]. IFN-β has also 
been shown to reduce mitochondrial RNA levels [61], which can be another mechanism 
by which IFN-β-induced hPNPaseold-35 plays a role in growth inhibition via its RNA 
degrading activity (Fig. 5) [22].   
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1.6.3 RNA degradation by hPNPaseold-35: In vitro mRNA degradation assays further 
validated that full-length hPNPaseold-35 or either of its two RNase PH domains can 
specifically degrade c-myc mRNA, whereas other mRNAs like c-jun, GAPDH or 
GADD34 are not affected (Fig. 5) [29,48]. The exact mechanism of how hPNPaseold-35 
specifically recognizes and degrades c-myc mRNA is still not clear, although our initial 
belief was that this may be mediated by a specific sequence in the 3’UTR of c-myc 
mRNA (as 3’UTRs contain various instability elements that act as important 
determinants of RNA turnover [62,63], as c-myc RNA devoid its 3’UTR was resistant to 
hPNPaseold-35 degradation [48,60]. Also, no specific RNA-binding site has been 
described in PNPase from any other species either, which is further confounded by the 
fact that in E.coli PNPase degrades a family of CSP (Cold-shock proteins) that do not 
show any sequence similarity [64]. Recent advances in studies involving substrate 
recognition by exoribonucleases have shown that RNA secondary structural elements 
may be primary determining factors in RNA binding and degradation rather than primary 
sequence. Future studies involving bioinformatics approaches and/or deletion/mutation 
analysis of c-myc 3’UTR mRNA sequence are required to better understand the 
importance of secondary structural elements in c-myc mRNA that allow its selective 
degradation by hPNPaseold-35.     
1.6.4 miRNA regulation by hPNPaseold-35: miRNAs are small, single-stranded, non-
coding RNAs, ~19-25 nucleotides in length that bind to a specific recognition sequence 
in the 3’UTR of their target mRNAs by complementary base pairing ultimately resulting 
in their cleavage and degradation or translational repression [65]. Genes encoding 
miRNAs have been found to be located in intergenic regions, within introns of protein 
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coding genes and also within introns and exons of non-protein coding genes [66]. They 
are transcribed in the nucleus by RNA polymerase II or III as primary or pri-miRNA 
consisting of a 60-80 nucleotide long stem loop structure. Precursor or pre-miRNA is 
generated by cleavage of pri-miRNA by an RNase complex DROSHA/DGCR8, which is 
then transported to the cytoplasm by Exportin-5. Further cleavage by an RNase Dicer 
results in the biogenesis of a double-stranded ~22 nucleotide miRNA which finally yields 
the mature miRNA after unwinding and stabilization by the Argonaute proteins [65,67].      
Regulation of gene expression by microRNAs was first discovered in C. elegans 
in 1993 and since then numerous miRNAs have been identified in plants and animal 
cells. The deregulation of miRNAs in various cancers and diseases has made them an 
active avenue of study that holds potential possibilities of therapeutic intervention [65]. 
Stemming from this interest, recently our group identified another novel mechanism by 
which hPNPaseold-35 causes growth inhibition by playing a significant role in post-
transcriptional modification of miRNA biogenesis [49,67]. In the quest to further 
understand hPNPaseold-35 functions as an exoribonuclease, a miRNA Microarray 
analysis performed after Ad.hPNPaseold-35 infection of melanoma cells resulted in the 
identification of specific miRNAs that were differentially regulated by hPNPaseold-35. 
Subsequent validation of downregulated miRNAs through immunoprecipitation, 
quantitative RT-PCR, northern blotting analysis and in vitro degradation assays showed 
that hPNPaseold-35 could specifically bind and degrade certain mature miRNAs like miR-
221, miR-222 and miR-106b, while having no effect on others like miR-184 and miR-
let7a (Fig. 6) [49]. Also, this downregulation by hPNPaseold-35 was limited to mature 
miRNAs only, primary and precursor miRNA were not affected, establishing a novel 
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hPNPaseold-35-mediated post-transcriptional regulatory mechanism of miRNA 
biogenesis. Apart from hPNPaseold-35 adenoviral overexpression studies, treatment of 
different melanoma cell lines with IFN-β (that induces hPNPaseold-35) also resulted in 
downregulation of miR-221 without having an effect on miR-184 or miR-let7a, which 
further strengthens the authenticity of this phenomenon in a more physiological setting. 
On the other hand, IFN-β treatment was unable to downregulate miR-221 in melanoma 
cells in which hPNPaseold-35 was knocked down and conversely, overexpression of miR-
221 made HO-1 cells resistant to IFN-β-mediated growth arrest. Interestingly, miR-221 
is a negative regulator of the p27Kip1 mRNA and accordingly this was identified as 
another pathway through which hPNPaseold-35 suppresses growth by downregulating 
miR-221 resulting in a subsequent increase in p27Kip1 levels (Fig. 6) [49]. The specific 
binding of hPNPaseold-35 to defined miRNAs can be sequence or secondary structure 
related, and this hypothesis needs to be further tested. 
1.6.5 hPNPaseold-35 and inflammation 
A characteristic feature of aging is chronic inflammation, which is also a hallmark 
of progressive degenerative diseases like Parkinson’s disease (PD), amyotrophic lateral 
sclerosis (ALS), atherosclerosis, Alzheimer’s disease (AD) and type 2 diabetes [68,69]. 
Aging is a phenomenon that is studied extensively, but at this point not a lot is known 
about the relationship between cellular senescence and inflammation. Damage that is 
caused by oxidative stress plays an important role in aging-associated inflammation, 
which is evident in tissues collected from aged individuals or aged experimental animals 
in the form of oxidative damage in their DNA, protein and lipids [70,71]. One of the 
important generators of reactive oxygen species (ROS) in the cell is mitochondria which 
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cause cumulative oxidative damage over time [68]. ROS have been known to regulate 
activity of the transcription factor NF-κB, which can turn on the expression of pro-
inflammatory cytokines like IL-6, IL-8, RANTES and MMP-3 [72,73]. In our adenoviral 
overexpression studies we found that hPNPaseold-35 localization in the mitochondria 
plays an important role in inducing ROS that leads to degradation of IκB-α, followed by 
nuclear translocation of the p65 subunit of NF-κB and increased p50/p65 NF-κB DNA 
binding resulting in increased production of pro-inflammatory cytokines as mentioned 
earlier [74,75]. The anti-oxidant N-acetyl-L-cysteine (NAC) could inhibit all of these 
events linked to aging-related inflammation, but does not protect cells from hPNPaseold-
35-induced growth inhibition [13,74]. Since hPNPaseold-35 expression is elevated during 
senescence and Ad. hPNPaseold-35 infection increases ROS production in the 
mitochondria (one possibility being that ROS could be generated as a result of 
mitochondrial protein turnover of hPNPaseold-35-substrates [76-78], a hypothesis that 
needs to be further tested), we can conclude that mitochondria-localized hPNPaseold-35 
plays a role in regulating the inflammatory components of senescence [74,79] . Also, 
given that hPNPaseold-35 is an early type I IFN-responsive gene and activation of IFN-
signaling pathway leading to the upregulation of IFN-regulated genes have been 
documented during the process of senescence [17,42,80] , these findings indicate that 
IFN might play an important role in regulating inflammatory diseases of aging [79]. 
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1.7 Functions of hPNPaseold-35 in mitochondria 
1.7.1 hPNPaseold-35 and mitochondrial homeostasis: The subcellular localization of 
hPNPaseold-35 in mitochondria has led to numerous studies aimed at trying to 
comprehend the role of hPNPaseold-35, if any in maintaining mitochondrial homeostasis 
and this has been done by classical gene knockdown and overexpression studies. The 
level of hPNPaseold-35 knockdown seems to play a critical role in deciding the 
observable changes in mitochondrial physiology and function [47,50]. An ~75% 
reduction in hPNPaseold-35 levels in HEK293T cells caused mitochondria to become 
filamentous and granular shaped, along with a three- to four-fold decrease in 
mitochondrial membrane potential (∆Ψ) and enzymatic activities of coupled respiratory 
complexes I and III, coupled complexes II and III, and individual complexes IV and V of 
the respiratory chain, accompanied by secondary changes like lactate accumulation and 
reduction of steady-state ATP levels [47]. Contradictory data is also available that 
shows no change in mitochondrial morphology or function in HeLa cells after 
hPNPaseold-35 knockdown [76]. Recent in vivo data representing a more physiological 
setting, has confirmed a role for hPNPaseold-35 in the maintenance of mitochondrial 
homeostasis, wherein mitochondria of liver-specific PNPT1 knockout mice show 
disordered, circular and smooth cristae along with a 1.5-2 fold decrease in activity of 
respiratory chain complex IV and complexes II+III+IV [44].                       
Overexpression of hPNPaseold-35 is found to cause an increase in ROS 
accumulation over time [74], which could be due to increased respiratory chain activity 
caused by mitochondrial dysfunction and implicates a role of hPNPaseold-35 in 
mitochondrial homeostasis maintenance. An exoribonuclease-independent role of 
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hPNPaseold-35 has also been highlighted in some studies wherein overexpressed 
hPNPaseold-35 plays a role in protecting cells from oxidized forms of RNA by limiting 
them from the translation mechanism [81,82].         
1.7.2 hPNPase and RNA import into mitochondria: Different RNA import pathways 
have been identified in various organisms but not much is known about the components 
involved [83,84]. New advances continue to be made, with one of the recent discoveries 
being the involvement of PNPase in regulating translocation of RNA into the 
mitochondria. It has been recently reported that PNPase regulates the import of 
nucleus-encoded small RNAs including RNase P RNA, MRP RNA, and 5S rRNA into 
the mitochondrial matrix by binding to specific stem-loop motifs in the imported RNAs 
[44,50]. Supporting this evidence is the proof that liver-specific PNPT1 knockout mice 
mitochondria showed a significant reduction in the RNA component of the RNase P 
mtRNA complex [44]. It should also be noted that PNPase mutations that inactivate 
RNA processing do not affect RNA import implying that these two functions are 
independent of each other. How PNPase makes the decision between RNA processing 
versus import is still an area that requires further experimentation [44,50].    
1.7.3 Role of hPNPase in mtRNA processing: Polyadenylation plays an important 
role in mtRNA metabolism and depending on the organism can lead to quick decay or 
increased stability of the transcript [85,86]. In contrast to bacteria and some eukaryotes 
where polyadenylation is catalyzed by poly(A) polymerases (PAPs) or PNPase, human 
mtRNA is polyadenylated by mitochondria-specific PAP. In order to answer the question 
whether hPNPase acts as a polymerase or exoribonuclease in mitochondria, it was 
silenced by shRNA treatment which resulted in an increase in the length of poly(A) tails 
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of mtRNA without having any effect on steady state levels of these mRNA species 
[47,76]. Another group showed that stable silencing of hPNPase had varied effects on 
different mt-mRNAs, and that polyadenylation of mtRNAs is performed by a polymerase 
distinct from both mtPAP and PNPase [87]. It is also suggested that hPNPase silencing 
causes ATP depletion which can alter the length of mtRNA polyI(A) tails [76,87]. Other 
studies suggest a role for hPNPase in complex with hSUV3 (human suppressor of Var1 
3) acting as degradation complex acting on double-stranded RNA in mammalian 
mitochondria, which hypothesizes a role for hPNPase in mitochondrial RNA degradation 
[78,88]. This degradation activity is suppressed by the LRPPRC/SLIRP (leucine-rich 
pentatricopeptide repeat motif-containing protein/ stem-loop-interacting RNA-binding 
protein) complex, which also promotes polyadenylation of mRNAs in the mitochondria 
[89]. In the light of all this information, it is clear that a lot more needs to be resolved 
before a clear picture of the role of hPNPase in mtRNA processing can be depicted 
(Fig. 1.6).     
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Fig. 1.6. Functions of hPNPaseold-35. hPNPaseold-35 is transcriptionally induced by 
the JAK/STAT pathway through IFN-β produced by the cell after viral infection, 
exposure to tumor cells, senescence-inducing signals or terminal-differentiation 
promoting signals. Next, hPNPaseold-35 is imported to the mitochondrial inner 
membrane space (IMS) by a YME- mediated mechanism or alternatively mobilized 
through an unknown mechanism to the cytoplasm where it causes growth arrest or 
apoptosis by targeting c-myc mRNA and miR-221 or activating PKR, respectively. 
Exposure to ionizing radiation inactivates hPNPaseold-35 by an EGFR-mediated 
mechanism, causing c-myc mRNA upregulation and increasing radioresistance of 
cancer cells. In the mitochondria hPNPaseold-35 maintains mitochondrial homeostasis, 
aids in RNA import, takes part in mtRNA processing/degradation events and 
increases ROS production that results in events leading to chronic inflammation.  
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CHAPTER TWO 
 
 
 
 
Gene Expression Signature of Human Polynucleotide Phosphorylase (hPNPaseold-
35) in Melanoma cells 
 
Part of the work presented in this chapter has been published in PLoS One 8(10): 
e76284 (2013).  
 
2.1 Abstract  
Human Polynucleotide Phosphorylase (hPNPaseold-35 or PNPT1) is an 
evolutionarily conserved 3’→5’ exoribonuclease implicated in the regulation of 
numerous physiological processes including maintenance of mitochondrial 
homeostasis, mtRNA import and aging-associated inflammation. From an RNase 
perspective, little is known about the RNA or miRNA species it targets for degradation 
or whose expression it regulates, except for c-myc and miR-221. To further elucidate 
the functional implications of hPNPaseold-35 in cellular physiology, we knocked-down and 
overexpressed hPNPaseold-35 in human melanoma cells and performed gene expression 
analyses to identify differentially expressed transcripts. Ingenuity Pathway Analysis 
indicated that knockdown of hPNPaseold-35 resulted in significant gene expression 
changes associated with mitochondrial dysfunction and cholesterol biosynthesis, 
whereas overexpression of hPNPaseold-35 caused global changes in cell-cycle related 
functions. Additionally, comparative gene expression analyses between our hPNPaseold-
	  	   26	  
35 knockdown and overexpression datasets allowed us to identify 77 potential “direct” 
and 61 potential “indirect” targets of hPNPaseold-35 which formed correlated networks 
enriched for cell-cycle and wound healing functional association, respectively. These 
results provide a comprehensive database of genes responsive to hPNPaseold-35 
expression levels, along with the identification of new potential candidate genes offering 
fresh insight into cellular pathways regulated by PNPT1 which may be used in the future 
for possible therapeutic intervention in mitochondrial- or inflammation-associated 
disease phenotypes.    
2.2 Introduction 
    Ribonucleases (RNases) are one of the central players involved in the regulation 
of post-transcriptional control of gene expression in both prokaryotes and eukaryotes 
[12,37]. They are divided into two main categories, endo- and exo-ribonucleases. 
Depending on the direction of degradation, exoribonucleases can be further classified 
as 5’→3’ or 3’→5’ exoribonucleases [90]. Numerous exoribonucleases identified in 
bacteria, Archaea and Eukarya have been placed under six major superfamilies, RBN, 
RNR, DEDD, PDX, RRP4 and 5PX [4,14]. Of these, the PDX family is the only one 
whose members use inorganic phosphate to generate nucleotide diphosphates instead 
of hydrolytic cleavage [14]. Polynucleotide phosphorylase (PNPase) is an evolutionarily 
conserved phosphorolytic 3’→5’ exoribonuclease that belongs to the PDX family of 
proteins [4] and it plays a major role in RNA metabolism in bacteria, plants and humans. 
The protein encoded by this gene consists of five conserved classical domains: two 
RNase PH domains, a α–helical domain and two RNA binding domains KH and S1 [91]. 
The human homolog of this gene (hPNPaseold-35) was identified in an overlapping 
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pathway screen (OPS) intended to identify upregulated transcripts in terminally 
differentiated human melanoma cells and senescent progeroid fibroblasts [17].  
    Human polynucleotide phosphorylase (hPNPaseold-35) is encoded by the PNPT1 
gene mapping to chromosome 2p15-2p16.1 and has been characterized as a type I IFN 
(IFN-α/β)-inducible early response gene [17,42]. Numerous endeavors over the past 
decade have enriched our comprehension of the workings of this exoribonuclease. It 
has become increasingly clear over the years that the various physiological functions of 
this enzymatic protein are not restricted to a single cellular compartment, in this case 
the mitochondrial inter membrane space (IMS) where it is primarily located [23,47]. In 
the cytoplasm this protein performs a myriad of functions, which include but are not 
restricted to degradation of mRNA and miRNA species [48,49]. Adenoviral-mediated 
overexpression of hPNPaseold-35 causes growth inhibition of normal and cancer cells 
characterized by morphological changes associated with senescence, G1/S or G2/M 
cell-cycle arrest and apoptosis [48,55,57,92]. The ability of hPNPaseold-35 to selectively 
degrade c-myc mRNA through its exoribonucleolytic activity has been identified as a key 
molecular mechanism mediating the growth suppressive effects of hPNPaseold-35, since 
overexpression of c-myc could only partially rescue these effects [48].  Apart from 
mRNA degradation, hPNPaseold-35 has also been identified as a direct regulator of 
mature miRNA species, specifically miR-221 that targets the cell cycle inhibitor p27Kip1 
[49,67]. Both these specialized functions of hPNPaseold-35 also implicate it as a direct 
mediator of IFN-β-induced growth inhibition [49,60]. Another novel function of 
hPNPaseold-35 is its ability to generate double-stranded RNA (dsRNA) through a currently 
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unknown mechanism, which ultimately leads to apoptosis of cells due to the activation 
of dsRNA-dependent protein kinase (PKR) [57].  
    Apart from the above-mentioned cytoplasmic functions that focus on its 
physiological roles in the regulation of growth inhibition and senescence, numerous 
roles of hPNPaseold-35 have been revealed that are central to its location in the 
mitochondria [13,67,75,93]. Overexpression of hPNPaseold-35 induces reactive oxygen 
species (ROS) production in the mitochondria resulting in the expression of pro-
inflammatory cytokines, which is a major phenomenon linking hPNPaseold-35 to aging-
related inflammation [74,79]. The significance of hPNPaseold-35 in maintaining 
mitochondrial homeostasis, with a specific relevance to the electron transport chain 
(ETC) components, has been revealed by hPNPaseold-35 knockdown studies in cell 
systems and also in a liver-specific knockout mouse model of hPNPaseold-35 [44,47]. 
There are also studies providing evidence that hPNPaseold-35 is a regulator of 
mitochondrial RNA import and plays a role in mtRNA processing [44,50,51,76,87]. 
Recently hPNPaseold-35 has also been shown to be present in the nucleus, and is 
associated with nEGFR protein, which regulates the exoribonuclease activity of 
hPNPaseold-35 upon exposure to ionizing radiations [75]. 
    Most of what we know about hPNPaseold-35 today has been gleaned from 
classical gain-of-function or loss-of-function experiments and from comparative studies 
performed through lessons acquired from its bacterial and plant counterparts [13,67,93]. 
Although these studies have been immensely valuable in illuminating the importance of 
hPNPaseold-35 in various physiological phenomena like senescence, growth-inhibition 
and mitochondrial dynamics, little is known about the specific network of genes that are 
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involved in these processes or which might be dysregulated when hPNPaseold-35 is 
aberrantly expressed. Moreover, when evaluating its function as an exoribonuclease, 
we know of only one mRNA and a single miRNA species that hPNPaseold-35 can 
degrade directly, c-myc and miR-221, respectively. Such findings led to our interest in 
trying to identify genes or gene networks that are either potential direct degradation 
targets of hPNPaseold-35 or regulated by hPNPaseold-35, respectively. In order to pursue 
this objective, we performed gene expression analysis on human melanoma cells in 
which hPNPaseold-35 was either silenced or ectopically overexpressed. Studying the 
global gene expression changes associated with hPNPaseold-35-knockdown or 
overexpression has provided valuable new insights regarding the functions of this 
elusive exoribonuclease while also validating previously known information. With the 
help of Ingenuity Pathway Analysis (IPA) we have identified key biological functions and 
associated genes that are deregulated in response to aberrant expression of 
hPNPaseold-35. Additionally, comparative analysis of the knockdown and overexpression 
datasets has allowed us to identify novel genes that may be directly or indirectly 
regulated by hPNPaseold-35.  
    In summary, our present studies interrogated the global implications of 
hPNPaseold-35 dysregulation and now provide a comprehensive database that can be 
further used not only to understand the biological functions of hPNPaseold-35 but also to 
identify candidate direct degradation targets such as c-myc and miR-221.  
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2.3 Materials and methods 
2.3.1 Cell culture 
   The human melanoma cell line HO-1 [53,95,96] was initially provided by Dr. 
Eliezer Huberman (Argonne National Laboratories, IL) maintained in Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen Life Technologies) supplemented with 10% 
fetal bovine serum (FBS; Sigma) and 5% penicillin/streptomycin (Gibco). The melanoma 
cell line WM35 [96-99], provided by Dr. Meenhard Herlyn (Wistar Institute) was 
maintained in MCDB153:Leibovitz’s L15 (4:1) pH 7.4 supplemented with 2% FBS and 
CaCl2 (1.68mM, Sigma). The hPNPaseold-35-knockdown stable cell lines were 
maintained in growth medium as described with the addition of 200 ng/ml (in case of 
HO-1 cells) or 300 ng/ml (in case of WM35 cells) of the selective antibiotic puromycin. 
All cell lines were maintained in a 5% CO2 95% O2 humidified incubator at 37°C. 0.5%. 
Trypsin-EDTA (10X) solution was purchased from Gibco and 1X Dulbecco’s Phosphate-
Buffered Saline (DPBS) from Corning Cellgro.   
2.3.2 Expression constructs, stable cell lines and viral infections 
   Lentiviral constructs (pGIPZ) expressing GFP were purchased from Open 
Biosystems. The constructs contained non-silencing short hairpin RNA (shRNA) or 
shRNAs against hPNPaseold-35 (PNPshRNA-1: clone ID V2LHS_17644, Mature Sense: 
GGCAACAGGAAATTAGAAA, Mature Antisense: TTTCTAATTTCCTGTTGCC; 
PNPshRNA-2: clone ID V2LHS_159887, Mature Sense: CAATAGGATTGGTCACCAA, 
Mature Antisense: TTGGTGACCAATCCTATTG). Lentiviruses encoding the different 
shRNAs were produced by cotransfecting the HEK-293T packaging cells with the 
appropriate pGIPZ constructs and the Trans-lentiviral Packaging Mix (Open 
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Biosystems) according to the manufacturer’s protocol. The supernatants containing the 
lentiviral particles were harvested 48 hours after transfection, concentrated by 
centrifugation and frozen at -80°C as aliquots. 1ml of the above viral suspension was 
used to transduce 3 x 105 HO-1 human melanoma cells grown in 6-cm dishes 
supplemented with 10 µg/ml polybrene. 48 hours post-transduction cells were 
trypsinized and replated at a low density (1:5) and complete media was added 
supplemented with positive selection marker puromycin to establish stable shRNA 
expressing single clones over a period of two weeks. Single clones isolated for 
PNPshRNA-1 and PNPshRNA-2 were screened to assess the level of knockdown at 
both the RNA and protein levels and the HO-1 clones with maximum hPNPaseold-35 
knockdown were used for microarray analyses (we used one of our HO-1 PNPshRNA-1 
clones for this purpose).  
    The construction and purification of replication-incompetent adenovirus encoding 
hPNPaseold-35 (Ad.hPNPaseold-35) has been described previously [17,48]. The empty 
vector Ad.vec was used as a control. For all adenoviral experiments, 1 x 105 cells were 
grown in 6-cm dishes and infected after 24 hours with Ad.vec or Ad.hPNPaseold-35 at a 
final m.o.i. of 5000 vp/cell diluted in 1 ml of serum-free media. After 6 hours of infection 
with shaking every 15 minutes, complete media was added and cells were harvested at 
the required time points (e.g., 36 hours post-infection) for microarray analysis, RNA or 
protein isolation.  
           All transient transfections were performed using Lipofectamine® 2000 
Transfection Reagent (Life Technologies) according to the manufacturer’s protocol. 
RNA and protein were harvested 48hrs post-transcfection for all experimental analyses.   
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2.3.3 RNA extraction, quality assessment and Microarray analyses 
   Total RNA from the hPNPaseold-35-knockdown cell line (HO-1 melanoma cells 
stably expressing shRNA-1 against hPNPaseold-35), HO-1 cells expressing non-silencing 
control shRNA, and HO-1 cells infected with Ad.hPNPaseold-35 or Ad.vec for 36 hours 
was isolated from cell lysates in TRIZOL reagent (InvitrogenTM Life Technologies, 
Carlsbad, CA). Cell lysates were subjected to an automated extraction method using 
the MagMAX™-96 for Microarrays Total RNA Isolation Kit (Ambion/InvitrogenTM Life 
Technologies, Carlsbad, CA) on the MagMAX™ Express Magnetic Particle Processor 
(Applied Biosystems/InvitrogenTM LifeTechnologies, Carlsbad, CA). 
    Gene expression profiles were ascertained using GeneChip® Human Genome 
U133A 2.0 (HG-U133A 2.0) arrays (Affymetrix, Santa Clara, CA) as previously 
described [100]. Every chip was scanned at a high resolution, with pixelations ranging 
from 2.5 µm down to 0.51 µm, by the Affymetrix GeneChip® Scanner 3000 according to 
the GeneChip® Expression Analysis Technical Manual procedures (Affymetrix, Santa 
Clara, CA). After scanning, the raw intensities for every probe were stored in electronic 
files (in .DAT and .CEL formats) by the GeneChip® Operating Software (GCOS) 
(Affymetrix, Santa Clara, CA). The overall quality of each array was assessed by 
monitoring the 3′/5′ ratios for a housekeeping gene (GAPDH) and the percentage of 
“Present” genes (%P); where arrays exhibiting GAPDH 3′/5′ < 3.0 and %P > 40% were 
considered good quality arrays [100]. All experiments were done in biological triplicates. 
The microarray data generated for this study are available online at the Gene 
Expression Omnibus repository under the accession number GSE46884. 
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2.3.4 Statistical Analysis, IPA and functional classification of genes 
    The Robust Multiarray Average method (RMA) was used for normalization and 
generating probe set expression summaries for the gene expression assays. To identify 
genes significantly altered among the different conditions (i.e., hPNPaseold-35 down-
regulation and up-regulation), t-tests were performed for each cell type. To adjust for 
multiple hypothesis testing, the resulting p-values were used to obtain the false 
discovery rates using the q-value method. Genes were considered significant using an 
FDR of 5%. All analyses were performed in the R statistical environment using functions 
provided by the BioConductor packages [100,101]. 
    In order to categorize biological functions related to gene expression altered by 
hPNPaseold-35 in our microarray analyses, we used the Ingenuity Pathway Analysis (IPA, 
Ingenuity® Systems, http://www.ingenuity.com) [102,103]. Genes were considered 
differentially expressed if they had q-values ≤ 0.05. The Affymetrix probe set IDs of 
significantly altered genes identified through the statistical analysis described above in 
both the hPNPaseold-35-knockdown and overexpression scenarios, along with their 
associated p- and q-values were uploaded into IPA and analyses performed. 
    The ToppFun function of the ToppGene suite of web applications [104] was used 
for the functional enrichment of the hPNPaseold-35-directly and indirectly regulated 
genes. The HGNC symbols for both the gene lists were uploaded and a FDR correction 
threshold of 5% was set for the subsequent functional enrichment analyses. The Gene 
Ontology (GO) categories (molecular function, biological process, and cellular 
component), biological pathway and gene and miRNA families were considered for 
analyses.     
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    In order to further validate if genes regulated by alterations in hPNPaseold-35 
expression formed gene interaction networks, the gene symbols for the potential 
hPNPaseold-35-“directly” and -“indirectly” regulated genes were uploaded into 
GeneMANIA (http://www.genemania.org), a web interface for generating interactive 
functional association networks [105]. This resource utilizes multiple external datasets, 
including protein-protein interactions and published microarray datasets, to form 
networks of potential gene-gene interactions. The interactive functional association 
networks obtained were generated based on co-expression, biological pathways, 
predicted association, genetic interactions, physical interactions and co-localization 
functional association data. The networks were generated using the query-dependent 
automatically selected weighting method. 
2.3.5 cDNA synthesis and quantitative real-time RT-PCR (qRT-PCR) 
    Total RNA was harvested from the hPNPaseold-35-knockdown and control stable 
cell lines and from the adenovirus infected HO-1 cells using the RNeasy purification kit 
(Qiagen). The quality and concentrations of isolated RNA samples were assessed using 
the NanoDrop 2000 (Thermo Scientific). 2 µg of RNA was used in a total volume of 20 
µl to synthesize cDNA using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) according to the manufacturer’s instructions. Real-time quantitative PCR 
was conducted using the ViiATM 7 Real-Time PCR System (Applied Biosystems) and 
performed in a total volume of 20 µl that contained the TaqMan Gene Expression 
Master Mix (Applied Biosystems), 1 µl of the cDNA template generated and the target-
specific TaqMan Gene expression assays (Applied Biosystems) according to following 
cycle parameters: 95°C for 10 minutes followed by 40 cycles at 95°C for 15 seconds 
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and at 60°C for 1 minute. Each sample was run in triplicate using three biological 
replicates and normalized to the housekeeping gene GAPDH used as an internal 
control in each case. The ΔΔCt method was used for comparing relative fold expression 
differences in the genes of interest between different test samples. Statistical 
significance (P<0.05) was determined using two-tailed student’s t-test and one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test wherever 
required.  
2.3.6 Protein isolation and Western blot analysis 
    Cells were harvested by centrifugation, pellets washed in PBS and subsequently 
lysed in ice-cold 1X cell lysis buffer (Cell Signaling) supplemented with PhosSTOP 
Phosphatase Inhibitor Cocktail Tablets and complete Mini Protease Inhibitor Cocktail 
Tablets (Roche), followed by centrifugation at 13,000 rpm for 15 minutes at 4°C. The 
supernatant or whole cell lysate was collected in a fresh tube and protein concentration 
was measured using the Bio-Rad Protein Assay Dye Reagent Concentrate (BIO-RAD). 
30 µg of total cell lysate was mixed with SDS sample buffer and heated for 5 minutes at 
95°C. The proteins were separated by 8-10% SDS-PAGE gels and transferred onto 
nitrocellulose membranes and blocked using 5% non-fat milk supplemented with 1% 
bovine serum albumin (BSA) in TBS-T for 1 hour. After washing three times with TBS-T 
for 10 minutes each, the membranes were incubated with primary antibodies overnight 
at 4°C. The primary antibodies used were anti-hPNPaseold-35 (chicken; 1:5000), anti-
EF1α (mouse, 1:1000). The next day membranes were washed as before and 
incubated with the relevant horseradish-peroxidase conjugated secondary antibodies for 
1 hour at room temperature. After washing three times with TBS-T for 10 minutes each, 
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the proteins were detected using ECL Western Blotting detection reagent (GE 
Healthcare Life Sciences) and exposed to X-ray film.  
2.3.7 Invasion assay 
          Cellular invasion was determined using a modified a Boyden chamber (BD 
BioCoatTM MatrigelTM Invasion Chambers (MIC) BD Biosciences, Catalog # 354480) by 
plating 5x104 HO-1 Csh or HO-1 PNPsh1 cl4/cl17 into cell well inserts in a 24-well plate 
provided by the manufacturer and according to the manufacturer’s instructions. After an 
incubation of 48 hrs at 37°C in the presence of 5% CO2 using DMEM (without serum) in 
both the top and bottom chambers; the number of cells that invaded through the 
matrigel were fixed with Solution A (fixative) for five minutes, which is a component of 
the Diff-Stain Kit (IMEB INC., Catalogue # K7148-2); next the wells were washed with 
water and the non-invading cells trapped in the matrigel layer were removed with the 
help of a cotton swab. The wells then were stained with Solution B (Azure stain) for 5-6 
minutes and counterstained with Solution C (xanthenes dyes) for 5-6 minutes. Finally 
the wells were lightly washed with water, dried and observed under the microscope. 
Five 10X fields were chosen randomly and the average number of invaded cells were 
counted. The data are represented as mean ± standard error of two independent 
experiments done in duplicate. Statistical significance (P≤0.05) was determined by one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test (Prism, 
GraphPad, San Diego, CA, USA).    
2.3.8 Immunohistochemistry 
          The multiple malignant melanoma tissue array slides with adjacent normal skin 
tissue were purchased from US Biomax Inc. (Catalogue # ME241a) and 
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immunohistochemistry was performed. The slides were incubated at 60°C for 1 hour in 
a vacuum chamber, followed by de-paraffination with two changes of xylene (5 minutes 
each). Next the slides were rehydrated with gradient alcohol, 100%, 95%, 80% and 70% 
for 3 minutes each, followed by incubating in water and PBS (phosphate buffer saline) 
for 5minutes each. Antigen retrieval was performed by incubating the slides in warm 
(95°C) Citrate-based antigen unmasking solution (Vector Laboratories, Inc., Catalogue 
# H-3300) in a vacuum chamber for 1 hour. Next the slides were rinsed in PBS for 5 
minutes and incubated in 2% H2O2 in PBS for 20 minutes. The slides were then blocked 
with 5% goat serum in PBS-T (0.1% Tween-20 in PBS) for 1 hour at room temperature 
and incubated with primary antibodies (anti-hPNPaseold-35 : chicken, 1:400; anti-EMR1: 
rabbit polyclonal (Origene, Catalogue # TA308395), 1:200) diluted in blocking buffer 
overnight at 4°C. The negative controls were also incubated in blocking buffer without 
any primary antibodies. The next day the slides were rinsed with PBS thrice for 5 
minutes each and incubated with biotinylated secondary antibodies (anti-chicken IgG, 
Catalogue # BA-9010, anti-rabbit IgG, Catalogue # BA-1000, 1:500, Vector 
Laboratories, Inc.) diluted in 2% goat serum in PBS-T for 1 hour at room temperature. 
Next the slides were rinsed with PBS thrice for 5 minutes each and incubated with 
VECTASTAIN® ABC reagent (Vector Laboratories, Inc.) for 30 minutes. After this the 
slides were washed with PBS thrice for 5 minutes each and incubated with freshly 
prepared ImmPACT DAB Peroxidase Substrate (Vector Laboratories, Inc., Catalogue # 
SK-4105) for 1-5 minutes. The slides were rinsed with water, counterstained with 
Hematoxylin QS nuclear counterstain (Vector Laboratories, Inc., Catalogue # H-3404) 
and rinsed with water again for 5-10 minutes. The slides were then dehydrated with 
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gradient alcohol, 70%, 80%, 95% and 100%, each 2-3 minutes, cleaned with xylene for 
5 minutes, dried and mounted with coverslip after addition of 1 drop of VectaMount™ 
Mounting Medium (Vector Laboratories, Inc., Catalogue #H-5000) and viewed under 
microscope.          
2.4 Results 
2.4.1 Melanoma cell culture model for studying hPNPaseold-35 regulated gene 
expression 
    In order to establish stable HO-1 human melanoma cell lines in which 
hPNPaseold-35 expression was silenced, we employed a lentiviral system to ensure 
efficient delivery. RNA and protein levels of hPNPaseold-35 were analyzed in the different 
single clones that survived after puromycin selection as described. Both the shRNAs 
tested, PNPshRNA-1 (data shown for clone 4) and PNPshRNA-2 (data shown for clone 
9), resulted in ≥80% and ~70% knockdown at the protein level as calculated by 
densitometric analysis(Fig. 2.1.A) relative to the scrambled control shRNA respectively. 
PNPshRNA-1 clone 4 was used for microarray analysis. The replication-deficient 
adenovirus for ectopic overexpression of hPNPaseold-35 has been extensively 
characterized previously [17,48]. Infection of HO-1 cells was performed as previously 
described [17,48] and both RNA and protein were analyzed for overexpression of 
hPNPaseold-35 (Fig. 2.1.B). RNA and protein from these cells were collected 36 h post-
infection for microarray analysis and a >30 fold increase in hPNPaseold-35 RNA levels 
and a 3 fold increase (as calculated by densitometric analysis) in hPNPaseold-35 protein 
levels was observed in the Ad.hPNPaseold-35 compared to the Ad.Vec treated cells.  
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Fig. 2.1. (A) Phase contrast LM (top) and GFP fluorescent micrographs (bottom) of 
HO-1 melanoma cell lines following transduction with GFP expressing scrambled 
shRNA and hPNPaseold-35 shRNA1 and 2 expressing lentiviruses and selection with 
puromycin. qRT-PCR expression of hPNPaseold-35 normalized to control 
(shScramble). Mean values normalized to a GAPDH internal reference; error bars 
represent mean ± S.E. of three replicate experiments, statistical significance was 
determined using one-way analysis of variance followed by Dunnett’s multiple 
comparison test. Anti-hPNPaseold-35 and EF1α loading control immunoblots and 
densitometric analysis graphically representing protein fold decrease. (B) qRT-PCR 
expression of hPNPaseold-35 in HO-1 cells infected with Ad.hPNPaseold-35 normalized 
to cells infected with Ad.Vec for 36 hour. Error bars represent mean ± S.E of three 
replicate experiments, statistical significance was determined using student’s t-test. 
Immunoblot showing hPNPaseold-35 overexpression compared to Ad.Vec post 36 hour 
of infection and densitometric analysis showing protein fold increase.  
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2.4.2 Genetic profile of hPNPaseold-35-knockdown melanoma cells 
    In order to further understand and possibly identify novel functions of hPNPaseold-
35, we stably depleted it using shRNA in HO-1 human melanoma cells (Fig. 2.1.A). The 
ability to study changes in gene expression patterns has become a valuable technique 
that permits evaluation of the significance of a gene in a more global context. Microarray 
analysis between the hPNPaseold-35 shRNA and the scrambled shRNA expressing HO-1 
cells led to the identification of a total of 1025 upregulated and 1364 downregulated 
transcripts which were altered significantly (FDR ≤ 0.05) (Fig. 2.2.B-C).      
 
Fig. 2.2. Venn diagrams representing number of genes significantly altered when 
hPNPaseold-35 is knocked down or overexpressed in human melanoma cells: Shown 
are total number of dysregulated genes (A), genes “directly” (B) and “indirectly” (C) 
regulated by hPNPaseold-35. 
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   We utilized IPA to functionally categorize all the differentially expressed genes 
identified following hPNPaseold-35 knockdown in HO-1 melanoma cells. The main 
molecular and cellular functions (p-values ranging from 3.92E-32 - 1.26E-03) associated 
with the most significantly altered genes were cell death and survival, cellular growth 
and proliferation, protein synthesis, cell cycle and RNA post-translational modification 
(Fig. 2.3, Table S1A). Based on these functional categories 25 biological gene networks 
were generated by IPA with a score ranging from 41 to 28 (Table S1D). IPA computes 
scores for each network based on p-values, which in turn indicate the likelihood of 
genes being found together in a network due to random chance. Higher the score, 
lesser the chance of the genes in a network being grouped together by random chance 
alone.  
 
Fig. 2.3. The biological functions and states associated with genes differentially 
expressed when hPNPaseold-35 is knocked down in human melanoma cells as 
identified by IPA. 
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Apart from classifying individual genes into functional categories, IPA also predicts 
corresponding biological pathways that may be significantly altered, along with 
mechanisms related to toxicity at a more biochemical level (Fig. 2.4).  
The most significant canonical pathways identified were related to EIF2 signaling, 
cholesterol biosynthesis, integrin signaling and mitochondrial dysfunction (Fig. 2.5, 
Table S1C).  
Fig. 2.4. Toxicologically related functionalities and pathways associated with genes 
dysregulated (proportions shown in graphs) after hPNPaseold-35 knockdown in 
melanoma cells, as identified by IPA Toxicogenomic Analysis.	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Even more fascinating was the finding that two of these biological pathways, cholesterol 
biosynthesis (Table 2.1) and mitochondrial dysfunction (Table 2.2), were directly 
correlated with predicted physiological toxicity (identified through IPA-Tox analysis) (Fig. 
2.4, Table S1B). HMGCR (Fig. 2.6.A), HMGCS1 and IDI1 were the three most 
significantly altered genes belonging to the cholesterol biosynthesis pathway. An overall 
downregulation of genes belonging to the electron transport chain and some associated 
factors was observed, consistent with previous observations regarding the role of 
hPNPaseold-35 in maintaining mitochondrial homeostasis [9,23]. Some of the significantly 
downregulated genes were NDUFA3, NDUFS1, UQCRFS1, COX6B1, C0X7A1, 
ATP5C1, CAT and UCP2 (Fig. 2.6.B). 
 
Fig. 2.5. Canonical pathways associated with genes differentially expressed when 
hPNPaseold-35 is knocked down in human melanoma cells. 
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Table 2.1. List of genes which are significantly altered as a result of hPNPaseold-35 
stable knockdown, and are associated with cholesterol biosynthesis, according to IPA 
Toxicogenomic Analysis. FDR≤0.05 = *, FDR≤0.01 = **, FDR≤0.005 = ***. 
Gene Symbol Gene Name Fold Change Affymetrix ID 
 ACAT2 acetyl-CoA acetyltransferase 2 -1.29 * 209608_s_at 
 DHCR7 7-dehydrocholesterol reductase -1.51 ** 201790_s_at 
 EBP emopamil binding protein (sterol isomerase) -1.22 * 213787_s_at 
 FDFT1 farnesyl-diphosphate farnesyltransferase 1 -1.23 * 210950_s_at 
 FDPS farnesyl diphosphate synthase -1.17 * 201275_at 
 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase -1.42 *** 202539_s_at 
 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(soluble) 
-1.56 *** 221750_at 
 IDI1 isopentenyl-diphosphate delta isomerase 1 -1.92 *** 208881_x_at 
 LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) -1.29 * 202245_at 
 MVD mevalonate (diphospho) decarboxylase -1.24 * 203027_s_at 
 SC5DL sterol-C5-desaturase (ERG3 delta-5-desaturase 
homolog, S. cerevisiae)-like 
-1.26 * 211423_s_at 
 SQLE squalene epoxidase -1.37 ** 209218_at 
Table 2.2. List of genes which are significantly altered as a result of hPNPaseold-35 
stable knockdown, and are associated with mitochondrial dysfunction, according to IPA 
Toxicogenomic Analysis. FDR≤0.05 = *, FDR≤0.01 = **, FDR≤0.005 = ***. 
Table 2A.  
ETC components Gene symbol Gene name 
Fold 
change Affymetrix ID 
 Complex I NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa -1.11 * 209224_s_at 
 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa -1.32 *** 218563_at 
 NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa -1.14 * 218160_at 
 NDUFA13 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 13 1.22 ** 220864_s_at 
 NDUFAB NADH dehydrogenase (ubiquinone) 1, -1.07 * 202077_at 
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1 alpha/beta subcomplex, 1, 8kDa 
 NDUFAF1 
NADH dehydrogenase (ubiquinone) complex 
I, assembly factor 1 -1.09 * 204125_at 
 NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa -1.09 * 218226_s_at 
 NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa -1.09 * 203621_at 
 NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa 1.36 ** 202839_s_at 
 NDUFS1 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 1, 75kDa (NADH-coenzyme Q 
reductase) 
-1.22 *** 
203039_s_at 
 NDUFS2 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 2, 49kDa (NADH-coenzyme Q 
reductase) 
-1.18 ** 
201966_at 
 NDUFS3 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 3, 30kDa (NADH-coenzyme Q 
reductase) 
-1.10 * 
201740_at 
 Complex II SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -1.11 * 202675_at 
 SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa -1.19 * 210131_x_at 
 Complex III UQCR10 ubiquinol-cytochrome c reductase, complex III subunit X -1.13 * 218190_s_at 
 UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI 1.22 ** 202090_s_at 
 UQCRFS1 
ubiquinol-cytochrome c reductase, Rieske 
iron-sulfur polypeptide 1 -1.32 *** 208909_at 
 Complex IV COX6B1 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) -1.31 *** 201441_at 
 Cytochrome c 
oxidase COX7A1 
cytochrome c oxidase subunit VIIa 
polypeptide 1 (muscle) -1.80 *** 204570_at 
 SURF1 surfeit 1 -1.17 ** 204295_at 
 Complex V ATP5A1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha subunit 1, 
cardiac muscle 
-1.12 ** 
213738_s_at 
 ATP synthase ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide -1.10 * 201322_at 
 ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
polypeptide 1 
-1.40 *** 213366_x_at 
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Table 2B.  
Mitochondria associated factors  
 Gene 
symbol  Gene name Fold change Affymetrix ID 
 AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 -1.11 *** 205512_s_at 
 APH1B anterior pharynx defective 1 homolog B (C. elegans) -1.37 ** 221036_s_at 
 BACE2 beta-site APP-cleaving enzyme 2 -1.11 * 217867_x_at 
 CAT catalase -1.45 *** 201432_at 
 CYB5R3 cytochrome b5 reductase 3 -1.10 * 201885_s_at 
 GLRX2 glutaredoxin 2 -1.28 * 219933_at 
 GPX4 glutathione peroxidase 4 1.21 * 201106_at 
 GSR glutathione reductase -1.31 * 205770_at 
 HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10 -1.13 * 202282_at 
 MAP2K4 mitogen-activated protein kinase kinase 4 1.44 * 203266_s_at 
 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 -1.15 * 200980_s_at 
 PSEN2 presenilin 2 (Alzheimer disease 4) -1.15 * 211373_s_at 
 PSENEN presenilin enhancer 2 homolog (C. elegans) -1.26 * 218302_at 
 SDHAP1 succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1 -1.19 ** 222021_x_at 
 TRAK1 trafficking protein, kinesin binding 1 1.18 * 202080_s_at 
 UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -3.22 *** 208998_at 
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Fig. 2.6. qRT-PCR verification of two most significant 
genes associated with (A) cholesterol biosynthesis and (B) 
mitochondrial dysfunction in hPNPaseold-35 silenced HO-1 
cells. Error bars represent mean ± S.E. of three replicate 
experiments. 
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2.4.3 Gene expression profile of Ad.hPNPaseold-35-infected melanoma cells 
    Overexpression of hPNPaseold-35 causes growth inhibition in a number of cancer 
types and the growth prohibitive effects have been attributed to the downregulation of c-
myc RNA by hPNPaseold-35.  We performed a microarray analysis of HO-1 cells infected 
with Ad.hPNPaseold-35 (Fig. 2.1.B) and compared the gene expression changes to cells 
infected with Ad.vec to identify transcripts differentially regulated as a result of 
hPNPaseold-35 overexpression. A total of 310 transcripts were upregulated and 407 were 
downregulated significantly (FDR ≤ 0.05) (Fig. 2.2).  
   Significant gene expression changes associated with adenoviral overexpression 
of hPNPaseold-35 could be classified into the following molecular and cellular functional 
categories according to IPA (p-values ranging from 7.50E-16 – 2.05E-03): cell cycle, 
cellular growth and proliferation, cell death and survival, DNA replication, recombination 
and repair and cellular development (Fig. 2.7, Table S2A). Based on these functional 
categories, 25 biological gene networks were generated by IPA with a score ranging 
from 46 to 19 (Table S2D).  
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The following are the most significant biological pathways altered when hPNPaseold-35 
was overexpressed: hereditary breast cancer signaling, p53 signaling, cell cycle control 
of chromosomal replication, IGF-1 and EIF2 signaling (Fig. 2.8, Table S2C).  
Fig. 2.7. The biological functions and states associated with genes differentially 
expressed when hPNPaseold-35 is overexpressed in human melanoma cells, as 
identified by IPA. 
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In order to understand if these pathways were relevant to any disease phenotype, we 
made use of the IPA-Tox analysis which identified p53 signaling, decreases in 
Transmembrane Potential of Mitochondria and Mitochondrial Membrane (Table 2.3) and 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation (Table 2.4) as some of the 
predicted significantly affected mechanisms (Fig. 2.9, Table S2B). The two main 
pathways we were interested to analyze further were the ones involved with cell cycle 
regulation and mitochondria, as there have been previous reports implicating a role for 
hPNPaseold-35 in both of these cellular functions [47,93].  
Fig. 2.8. Canonical pathways associated with genes differentially expressed when 
hPNPaseold-35 is overexpressed in human melanoma cells. 
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Overexpression of hPNPaseold-35 causes growth inhibition, which is partially attributed to 
downregulation of c-myc [48], so it was not surprising to observe changes in gene 
expression related to cell cycle regulation. Some of the most significantly altered genes 
in this category were CCNB2, CDK1, CHEK2 and KAT2B. Another interesting 
observation was the dysregulation of mitochondrial homeostasis, which again 
emphasizes a role of hPNPaseold-35 in the mitochondria. These gene expression 
changes could be due to a direct role that hPNPaseold-35 plays in the mitochondria or 
affects associated with growth inhibition caused by hPNPaseold-35 overexpression. Some 
of these significantly altered genes were FAS, BCL2L11 and BIRC5 (Table 2.3).           
 
 
 
 
Fig. 2.9. Toxicologically related functionalities and pathways associated with genes 
dysregulated (proportions shown in graphs) after hPNPaseold-35 overexpression in 
melanoma cells, as identified by IPA Toxicogenomic Analysis. 
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Table 2.3. List of genes which are significantly altered as a result of hPNPaseold-35 
overexpression, and are functionally associated with the maintenance of mitochondrial 
transmembrane potential, according to IPA Toxicogenomic Analysis. FDR≤0.05 = *, 
FDR≤0.01 = **, FDR≤0.005 = ***. 
Gene Symbol Gene Name Fold Change Affymetrix ID 
 APAF1 apoptotic peptidase activating factor 1 1.113** 211553_x_at 
 BARD1 BRCA1 associated RING domain 1 -1.414** 205345_at 
 BCL2L11 BCL2-like 11 (apoptosis facilitator) 1.351** 222343_at 
 BIRC5 baculoviral IAP repeat containing 5 -1.312** 202094_at 
 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 -1.280** 201848_s_at 
 CD47 CD47 molecule 1.148** 213857_s_at 
 CHEK2 checkpoint kinase 2 -1.387** 210416_s_at 
 CHMP5 charged multivesicular body protein 5 1.715** 218085_at 
 FAS Fas (TNF receptor superfamily, member 6) 1.450** 204781_s_at 
 IFI6 interferon, alpha-inducible protein 6 1.345** 204415_at 
 NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 -1.404** 209239_at 
 SLC25A14 solute carrier family 25 (mitochondrial carrier, brain), member 14 -1.155** 204587_at 
 SOD2 superoxide dismutase 2, mitochondrial 1.384** 216841_s_at 
 TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 1.423** 201042_at 
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Table 2.4. List of genes which are significantly altered as a result of hPNPaseold-35 
overexpression, and are associated with G2/M DNA damage checkpoint regulation, 
according to IPA Toxicogenomic Analysis. FDR≤0.05 = *, FDR≤0.01 = **, FDR≤0.005 = 
***. 
Gene Symbol Gene Name  Fold Change Affymetrix ID 
 BRCA1 breast cancer 1, early onset -1.235** 211851_x_at 
 CCNB2 cyclin B2  -1.217** 202705_at 
 CDK1 cyclin-dependent kinase 1 -1.496** 203214_x_at 
 CHEK2 checkpoint kinase 2  -1.387** 210416_s_at 
 KAT2B K(lysine) acetyltransferase 2B 1.520** 203845_at 
 SKP1/SKP1P2 S-phase kinase-associated protein 1 1.173** 207974_s_at 
 YWHAB 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide 
-1.139** 217717_s_at 
 YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
1.332** 200639_s_at 
 
2.4.4 Identification of genes regulated by hPNPaseold-35  
    Bearing in mind that hPNPaseold-35 is functionally an exoribonuclease, there could 
be two major mechanisms through which it could modulate gene expression; it could 
either degrade target genes directly (“direct regulation”) or it could degrade miRNAs (or 
mRNAs for other regulatory proteins) that in turn are regulators of certain genes 
(“indirect regulation”). Since we had gene expression patterns corresponding to both 
hPNPaseold-35 overexpression and knockdown, we employed stringent criteria to identify 
genes that could be directly or indirectly regulated by hPNPaseold-35. Instead of making 
the obvious choice of selecting genes that were inversely related to the expression of 
hPNPaseold-35 in either microarray dataset, we performed an overlapping screen with the 
help of the online tool VENNY [106] in order to identify transcripts whose expressions 
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changed inversely in both the datasets. This comparison resulted in the identification of 
77 potential hPNPaseold-35-directly regulated genes that were up-regulated when 
hPNPaseold-35 was depleted and down-regulated when hPNPaseold-35 was 
overexpressed (Fig. 2.2.B; Table S3A, B). A second set of 61 transcripts that were 
downregulated when hPNPaseold-35 was depleted by shRNA and up-regulated when 
hPNPaseold-35 was overexpressed were also taken in consideration as potential 
hPNPaseold-35-indirectly regulated genes (Fig. 2.2.C; Table S3C, D). All the genes in 
these lists were significant with q-values ≤ 0.05.  
    In order to place the hPNPaseold-35-regulated genes into functional categories, we 
made use of the ToppFun function of the ToppGene suite of web applications. A 
summary of the GO categories with the maximum number of genes and the most 
significant p-values is provided in Table 2.5.  
Table 2.5. Functional and structural categories of genes associated with 
hPNPaseold-35-driven regulation. 
Functional category Source p-value no. of genes 
 “Directly” regulated genes    
 RNA binding GO: Molecular Function 6.21E-05 13/894 
 Chromosome organization GO: Biological Process 1.28E-06 19/751 
 Cell cycle GO: Biological Process 1.28E-06 25/1460 
 Chromosome GO: Cellular Component 1.46E-10 21/671 
 Mitotic Prometaphase pathway MSigDB 3.62E-02 6/92 
 “Indirectly” regulated genes    
 Response to wounding GO: Biological Process 5.43E-03 16/1168 
 Vacuole GO: Cellular Component 4.74E-03 9/424 
 Integral to plasma membrane GO: Cellular Component 4.81E-02 13/1328 
 CD molecules 
Gene Family 
(genenames.org)  3.45E-04 5/276 
 miR-124a MicroRNA (PicTar) 4.04E-02 11/626 
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The hPNPaseold-35-directly regulated genes represent significant enrichment related to 
RNA binding, chromosome organization and cell cycle associated (CENPE, MKI67, 
POLD3, MCM4) functions (Table S4A). To determine how the hPNPaseold-35-regulated 
genes might interact with each other, gene symbols were uploaded into GeneMANIA. 
The directly-regulated genes form a densely correlated network with overlapping 
functional categories akin to organelle fission, chromosome segregation and DNA 
strand elongation as predicted by the gene functional analysis (Fig. 2.10). There was an 
over-representation of genes related to cellular response to wounding (TGM2, SDC2, 
MCAM), genes belonging to the CD family of cell surface receptors (DDR1, JAG1, 
CD164, MCAM, CD47), and miR-124a predicted targets (SLC7A8, JAG1, SDC2, 
CADM1, RNF128) in the hPNPaseold-35-indirectly regulated genes dataset (Table S4B). 
These probe sets also form a network cluster comprised mainly of co-expressed genes 
(Fig. 2.11). The inter-gene correlations between probe sets defined as being potentially 
directly or indirectly regulated by hPNPaseold-35 were largely based on publically 
available co-expression association data.  
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Fig. 2.10. Network visualization of genes potentially “directly” regulated by 
hPNPaseold-35. 
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In order to confirm select genes from the microarray analyses (microarray fold changes 
provided in Table S3), five potential hPNPaseold-35-regulated genes were validated (for 
the purpose of this study we validated only a few genes as it was not feasible to validate 
all the hPNPaseold-35-regulated genes identified) by qRT-PCR to show their inverse 
Fig. 2.11. Network visualization of genes potentially “indirectly” regulated by 
hPNPaseold-35.  
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correlation with hPNPaseold-35 expression in the HO-1 melanoma cell line as shown in 
Figs. 2.12 and 2.13 (putative “direct target”: CENPE, MKI67; putative “indirect targets”: 
VGF, RNF128). CENPE and MKI67 were chosen for validation as they were also 
identified in an overlapping screen we performed between hPNPaseold-35-knockdown 
cells and a doxycycline inducible hPNPaseold-35 overexpression system in HeLa cells 
(Chapter 3) and showed a 20-40% increase upon hPNPaseold-35 knockdown and >40% 
decrease following hPNPaseold-35 overexpression at the RNA level. VGF and RNF128 
were chosen as they showed the maximum fold change in the hPNPaseold-35-
knockdown cells and showed >40-80% decrease by qRT-PCR following hPNPaseold-35 
knockdown and ~20-50% increase following hPNPaseold-35 overexpression. Statistical 
analysis determined using one-way analysis of variance followed by Dunnett’s multiple 
comparison test in case of hPNPaseold-35 knockdown samples and by a two tailed 
student’s t-test in case of hPNPaseold-35 overexpression samples, where *= P< 0.05, **= 
P< 0.01 and ***=P< 0.001. 
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Fig. 2.12. qRT-PCR verification of hPNPaseold-35-putative “directly” regulated genes 
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B) 
overexpression in HO-1 melanoma cells. Error bars represent mean ± S.E. error of 
three replicate experiments. 
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Transient knockdown of hPNPaseold-35 using siRNA also showed the inverse correlation 
of hPNPaseold-35 expression with potential direct targets CENPE, MKI67 (qRT-PCR 
validation showed a ~20% increase in both) and indirect targets VGF, MCAM (qRT-PCR 
validation showed a ~20% decrease in both) (Figure 2.14). Statistical analysis 
determined using a two tailed student’s t-test, where *= P< 0.05, **= P< 0.01 and ***=P< 
0.001. 
 
Fig. 2.13. qRT-PCR verification of hPNPaseold-35-putative “indirectly” regulated genes 
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B) 
overexpression in HO-1 melanoma cells. Error bars represent mean ± S.E. of three 
replicate experiments. 
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Fig. 2.14. (A) qRT-PCR expression of hPNPaseold-35 following transient transfection 
with siRNA against hPNPaseold-35 normalized to scrambled control post 48 hour. 
Immunoblot showing hPNPaseold-35 levels after siRNA transfection. (B) qRT-PCR 
verification of hPNPaseold-35-putative (i) “directly” and (ii) “indirectly” regulated genes 
after hPNPaseold-35 transient silencing post 48 h. Error bars represent mean ± S.E. of 
two replicate experiments. 
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The expression changes of four putative hPNPaseold-35-directly and indirectly regulated 
genes were also validated using another melanoma cell line WM35 (Figs. 2.15-17). 
MKI67 and CENPE showed a 1.2 and 1.5 fold increase at the RNA level following 
hPNPaseold-35 knockdown respectively. Following hPNPaseold-35 overexpression in 
WM35 cells, MKI67 and CENPE levels reduced 30 and 20% respectively. Both VGF 
and MCAM RNA levels reduced 20% upon hPNPaseold-35 knockdown. Overexpression 
of hPNPaseold-35 resulted in a 1.2 and 1.4 fold increases in MCAM and VGF RNA levels. 
Statistical significance was determined using a two-tailed student’s t-test.  
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Fig. 2.15. (A) Phase contrast LM (top) and GFP fluorescent micrographs (bottom) of 
WM35 melanoma cells following transduction with GFP expressing scrambled 
shRNA and hPNPaseold-35 shRNA1 expressing lentiviruses and selection with 
puromycin. qRT-PCR expression of hPNPaseold-35 (hPNPaseold-35 knockdown) 
normalized to control (shScramble). Mean values normalized to a GAPDH internal 
reference; error bars represent mean ± S.E. of three replicate experiments. Anti-
hPNPaseold-35 and EF1α loading control immunoblots. (B) qRT-PCR expression of 
hPNPaseold-35 in WM35 cells infected with Ad.hPNPaseold-35 normalized to cells 
infected with Ad.Vec for 36 hour. Immunoblot showing hPNPaseold-35 overexpression 
compared to Ad.Vec post 36 hour of infection. Error bars represent mean ± S.E. of 
three replicate experiments. * P < 0.02, ** P < 0.01. 
	  
Fig. 2.16. qRT-PCR verification of hPNPaseold-35-putative “directly” regulated genes 
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B) 
overexpression in WM35 melanoma cells. Error bars represent mean ± S.E. of two 
replicate experiments done in triplicate. 
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Finally, some of the hPNPaseold-35 direct and indirect targets were validated by qRT-
PCR in two additional melanoma cell lines (C8161 and MeWo) following transient 
knockdown of hPNPaseold-35 in order to show that the decrease or increase in transcript 
levels was not due to indirect effects of stable knockdown. Direct target CENPE showed 
a ~1.2 fold increase in C8161 and MeWo cells both; MKI67 showed a 1.2 fold increase 
in C8161 cells at the RNA level. Levels of indirect targets MCAM and RNF128 
decreased 40 and 50% in C8161 cells and 10 and 20% in MeWo melanoma cells.    
Fig. 2.17. qRT-PCR verification of hPNPaseold-35-putative “indirectly” regulated genes 
identified by microarray analyses in response to hPNPaseold-35 (A) knockdown or (B) 
overexpression in WM35 melanoma cells. Error bars represent mean ± S.E. of two 
replicate experiments done in triplicate.	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Fig. 2.18. qRT-PCR expression of hPNPaseold-35 following transient 
transfection with siRNA against hPNPaseold-35 normalized to scrambled 
control post 48 h in C8161 (A) and MeWo (B) melanoma cells.  Error bars 
represent mean ± S.E. of two replicate experiments. Statistical significance 
determined using two-tailed student’s t-test, *P<0.05, **P<0.01, ***P<0.001. 	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2.4.5 hPNPaseold-35  stable knockdown in melanoma cells and invasion 
Analysis of the microarray results following hPNPaseold-35 stable knockdown in 
HO-1 melanoma cells revealed gene expression changes in numerous genes 
associated with cellular invasion. Thus we decided to analyze any effect that stable 
knockdown of hPNPaseold-35 may have on cellular invasion using matrigel based Boyden 
chambers. We observed that stable knockdown of hPNPaseold-35 in HO-1 melanoma 
cells resulted in a ~2-3 fold increase in in vitro invasion in two hPNPaseold-35 knockdown 
clones we tested (Figure 2.19A). Next we checked the relative mRNA levels of a few of 
the genes that maybe related to cellular invasion based on our knowledge of current 
literature. We observed a ~6-10 fold increase in the levels of EMR1 (egf-like module 
containing, mucin-like, hormone receptor-like 1; a gene that was the most upregulated 
(3 fold) transcript in our hPNPaseold-35 knockdown microarray results), a ~2 fold increase 
in MMP2 (matrix metallopeptidase 2) , FN1 (fibronectin 1) and CADM3 (cell adhesion 
molecule 3) (Figure 2.19B). MMP2 and FN1 are well-studied proteins that have been 
known to be involved in the invasion-related functions of numerous cancer cell types, 
and currently we believe that the slight increase we observe in their levels could be an 
indirect effect (could be miRNA related) of hPNPaseold-35 knockdown rather than a direct 
effect mediated by hPNPaseold-35 degradation of these transcripts. On the other hand, 
there are no known reports relating EMR1 or CADM3 to invasion, but we were 
interested to pursue them, as they are cell surface receptors and could potentially play a 
role in cell-cell signaling events. There are some studies where the homologues of 
EMR1, EMR2 and 3, have been associated with poor prognosis and an invasive 
phenotype in glioblastoma. Thus we decided to check EMR1 levels in another 
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melanoma cell line, WM35 following stable hPNPaseold-35 knockdown, but we did not 
observe an increase in its levels, instead we observed a decrease (Figure 2.20). Thus 
at the current moment we believe that EMR1 is probably an indirect target of 
hPNPaseold-35 whose levels may probably be regulated by certain miRNA species and 
the modest increase in invasion we observe following hPNPaseold-35 knockdown in HO-1 
melanoma cells may be attributed to the cumulative upregulation of cellular invasion 
related genes like EMR1, MMP2, FN1. Future studies in additional melanoma cell lines 
would be required and levels of other invasion related genes (levels of other EMR1 
homologues like EMR2 and 3 may also be checked) or miRNAs would need to be 
determined in order to evaluate the mechanism behind the increase in cellular invasion 
observed following stable hPNPaseold-35 knockdown.   
Since we saw an increase in EMR1 levels upon hPNPaseold-35 knockdown at 
least in HO-1 melanoma cells, we were still interested to pursue this molecule further 
and see if there was any correlation between EMR1 and hPNPaseold-35 levels in tumor 
versus normal tissue samples to analyze if there was any potential biological 
significance of this hypothesized indirect effect of hPNPaseold-35 knockdown on EMR1 
levels. In order to do this we purchased multiple melanoma tissue array slides with 
tissue sections from normal and different tumor stages and performed 
immunohistochemistry (IHC) with hPNPaseold-35 and EMR1 specific antibodies. Visual 
observation of the stained IHC slides showed that EMR1 levels seem to increase and 
hPNPaseold-35 levels decrease with tumor stage (Stage II-IV) (Figure 2.21). Also the 
adjacent normal tissue sections seem to have higher levels of hPNPaseold-35 and lower 
levels of EMR1 compared to their tumor counterparts. From this preliminary result we 
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can conclude that there seems to be an inverse correlation between hPNPaseold-35 and 
EMR1 levels, which may or may not be due to hPNPaseold-35 direct or indirect regulation. 
Future studies would be required to further explore this premise and as suggested 
earlier, identification of hPNPaseold-35 –degradable miRNA species regulating EMR1 
may allow recognition of therapeutic opportunities for cancers with high levels of EMR1. 
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Fig. 2.19. hPNPaseold-35 knockdown and invasion of HO-1 melanoma cells (A) 
Invasion assay images and graphical representation of invasion assay results of scrambled 
shRNA control and hPNPaseold-35 shRNA stably transduced HO-1 melanoma cells. Error bars 
represent mean ± standard error of two independent experiments done in duplicate. (B) qRT-
PCR validation of invasion related genes identified in microarray results. Error bars represent 
mean ± standard error of three independent experiments done in triplicate. Statistical 
significance was determined using a one-way analysis of variance followed by Dunnett’s 
multiple comparison test. *P<0.05, **P<0.01, ***P<0.001. 	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Fig. 2.20. qRT-PCR validation of hPNPaseold-35 and EMR1 levels in WM35 
melanoma cells following stable hPNPaseold-35 knockdown. Error bars represent 
mean ± standard error of two independent experiments done in triplicate. **P<0.01.	  
Fig. 2.21. Representative images of immunohistochemistry analysis of multiple 
malignant melanoma tissue arrays.	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2.5 Discussion  
    Numerous studies performed over the past decade have utilized the RNAi 
methodology to evaluate the functions of hPNPaseold-35. Most of these studies 
concentrated on studying the role of hPNPaseold-35 in reference to its mitochondrial 
location with special emphasis on mtRNA processing, maintenance of mitochondrial 
homeostasis and more recently its role in mitochondrial RNA import 
[44,47,50,51,76,87]. In other studies, overexpression of hPNPaseold-35 has been shown 
to cause growth inhibition attributed to downregulation of c-myc and miR-221 by its 
exoribonuclease activity in the cytosol [48,49]. In this study we have incorporated both 
these classic genetic approaches of gene knockdown and overexpression to further 
understand hPNPaseold-35 functions on a more comprehensive level. This is the first 
attempt of its kind aimed at studying global gene expression changes resulting from 
hPNPaseold-35 knockdown or overexpression in order to identify unique genes regulated 
by hPNPaseold-35. In this manuscript we focus on the analysis of gene expression 
patterns of the most relevant biological pathways of hPNPaseold-35 potential functions. 
     Our results show that stable knockdown of hPNPaseold-35 in melanoma cells 
affects mitochondrial function and cholesterol biosynthesis. Other groups have 
previously reported the importance of hPNPaseold-35 in the maintenance of mitochondrial 
homeostasis through knockdown and liver specific knockout experiments where they 
showed a deregulation of the various respiratory complexes in the Electron Transport 
Chain (ETC) following hPNPaseold-35 silencing [44,47]. These results further strengthen 
those findings. In this study we report novel genes (Table 2.2) that encode for proteins 
constituting the various ETC respiratory complexes, which were differentially expressed 
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in our hPNPaseold-35 knockdown melanoma cells. Some mitochondrial accessory factors 
were also affected and one of them UCP2 [107], which is a mitochondrial anion 
transporter that plays a role in energy dissipation and maintenance of mitochondrial 
membrane potential was downregulated ~3-fold (Fig. 2.6.B). The exact mechanism of 
how hPNPaseold-35 regulates these genes remains to be elucidated and the possibilities 
may be numerous ranging from RNA degradation, miRNA regulation or RNA import. 
Moreover, recently mutations in hPNPaseold-35 have also been identified that impair 
respiratory-chain activity [108]. The ETC genes identified in this study identify the 
specific genes affected by hPNPaseold-35 that maybe causative for mitochondrial 
dysfunction. Further studies aimed at understanding the functional implications of the 
identified genes may provide valuable insight to the physiological role of hPNPaseold-35 
in mitochondrial diseases and discovering suitable therapeutic options.  
    We also identified genes belonging to the cholesterol biosynthesis pathway that 
were significantly downregulated with depletion of hPNPaseold-35. This is a novel and 
potentially biologically important result since association of hPNPaseold-35 with this 
pathway has not been previously reported. Mitochondrial dynamics have been linked to 
steroid biosynthesis and the gene expression changes we observed pertaining to 
cholesterol biosynthesis could be a consequence of mitochondrial dysfunction, or vice 
versa. Additionally, since this analysis was performed in a stable cell line in which 
hPNPaseold-35 was silenced, certain compensatory changes could be acquired over time 
as opposed to primary effects of gene knockdown. On the other hand hPNPaseold-35 
could indeed directly regulate the RNA levels of these genes or alter their expression by 
regulating upstream transcriptional control elements. SREBF2 is one such transcription 
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factor that was found to be downregulated 1.3-fold in our microarray analyses which 
regulates the expression of HMGCR (Fig. 2.6.A), HMGCS1 and IDI1. Further studies to 
address and evaluate these possibilities would be required to assess the relevance of 
hPNPaseold-35 in this context. 
    Previous studies have shown that adenoviral overexpression of hPNPaseold-35 
induces growth suppression and a senescence-like phenotype [17,48]. Our present 
analyses show that the majority of genes differentially expressed as a result of 
adenoviral overexpression of hPNPaseold-35 compared to the empty vector control 
(Ad.Vec) belong to cell cycle, cellular assembly and organization categories. Biological 
pathways likely affected as a consequence of the gene expression changes included 
cell cycle control of chromosomal replication. Key genes down-regulated more than 1.5-
fold in this category belonged to the mini-chromosome maintenance complex (MCM2, 
MCM4-7) that is essential for eukaryotic DNA replication. Important regulators of G2/M 
DNA damage checkpoint control; CCNB2, CHEK2 and CDK1 were also downregulated. 
The gene expression changes of these cell-cycle regulators may contribute towards 
tipping the balance in the cell in the direction of growth inhibition. Also, changes in gene 
expression were identified in apoptosis regulatory molecules. FAS, BIK and BCL2L11 
(pro-apoptotic) expression was increased and BIRC5 (anti-apoptotic) levels were 
reduced significantly, which may have played a role in decreasing the transmembrane 
potential of the mitochondrial membrane observed upon hPNPaseold-35 overexpression 
in the IPA analyses, an important phenomenon implicated in apoptosis [109]. These 
findings provide new information regarding the cell-cycle associated implications of 
hPNPaseold-35 overexpression and provide targets for further studies. These findings are 
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also supported by previous studies; where it was shown that terminal differentiation 
(which shares overlapping characteristics with cellular senescence) of HO-1 melanoma 
cells caused by combination treatment with IFN-β plus the protein kinase C activator 
mezerein resulted in global gene expression reductions of cell-cycle associated genes 
[110,111]. hPNPaseold-35 is a Type I-IFN inducible early response gene [42]; thus it was 
not surprising that we observed a similar pattern of gene expression changes in our 
present study involving hPNPaseold-35 overexpression. The candidate genes identified 
may also provide insight regarding the role of hPNPaseold-35 in aging-associated 
inflammation [74,79]. Some of the potentially biologically significant genes in this 
category were CAPN3, BIRC5, TRIM2, CENPF, FN1, BCL6 and GMNN. This premise 
needs further attention, as it is evident that the cell-cycle changes associated with 
hPNPaseold-35 overexpression are diverse and complex. Also, c-myc is a key regulator of 
cell-cycle progression, which is targeted by hPNPaseold-35 for degradation. Bearing this 
in mind, in the present study we chose an earlier time point of 36 hours, before changes 
in the c-myc transcript levels were evident, to study Ad.hPNPaseold-35 associated gene 
expression changes. Even so, in order to identify genes directly targeted by hPNPaseold-
35 irrespective of c-myc status we plan to study the effects of hPNPaseold-35 
overexpression in a c-myc null background [112,113].  
    To identify additional genes regulated by hPNPaseold-35, we ascertained 
transcripts in our two separate datasets (i.e. hPNPaseold-35 knockdown and 
overexpression) whose expression inversely correlated with hPNPaseold-35. This novel 
strategy helped us detect 77 potential “directly” (mRNA degraded by hPNPaseold-35) and 
61 potential “indirectly” (miRNAs targeting these transcripts degraded by hPNPaseold-35) 
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regulated transcripts. Although in this study we have concentrated on this small list of 
genes identified through the overlapping approach between our hPNPaseold-35 depleted 
and overexpression datasets, future studies would be required to analyze the remaining 
genes whose expression is also regulated by hPNPaseold-35 but do not fall in this list 
(Figs. 2.2.B-C). Most of these potential “direct” targets were genes implicated in cell-
cycle associated functions and two of them have been validated by qRT-PCR; CENPE 
(Centromere protein E) which is involved in mitotic checkpoint control [114,115] and 
MKI67 (antigen identified by monoclonal antibody Ki-67), a known cellular proliferation 
marker implicated in rRNA synthesis [116-118]. Since most of the genes thought to be 
“directly” regulated belong to a closely associated network of cell cycle regulatory 
functions, at this point it is difficult to say whether these gene expression changes 
represent global effects of hPNPaseold-35 deregulation caused by key upstream 
regulators or if they are genes that are directly targeted by hPNPaseold-35 for 
degradation. Future studies using in vitro mRNA degradation assays will help answer 
these questions. Among the “indirectly” regulated targets, a fraction of genes were 
identified that had conserved sites for miR-124a (Table S4). We validated one of these 
genes by qRT-PCR; RNF128 (ring finger protein 128) an E3 ubiquitin ligase that is 
involved in the regulation of cytokine gene transcription [119]. Another potential indirect 
target we validated was VGF (VGF nerve growth factor inducible), which encodes a 
neuro-endocrine polypeptide implicated in a vast array of biological phenomena that 
include energy metabolism and inflammation [120-122]. Identification and subsequent 
validation of miRNAs targeting the genes we identified would aid in clarifying the role of 
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hPNPaseold-35, if any, in the context of the relevant biological processes these genes are 
implicated in and would further allow appropriate therapeutic intervention. 
    In summation, this study has produced a novel genetic and genomic analysis of 
the functional implications for alterations in PNPT1 gene expression.  Our analysis has 
identified a limited set of candidate genes for direct regulation by hPNPaseold-35. Such 
genes could provide novel targets for intervention in hPNPaseold-35-related disease 
states. Furthermore, this work has generated a comprehensive database of hPNPaseold-
35-responsive genes that are potentially relevant to the mechanisms of global cellular 
functions affected by this important regulatory molecule. 
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CHAPTER THREE 
 
 
 
 
Analysis of global changes in gene expression induced by human polynucleotide 
phosphorylase (hPNPaseold-35) 
 
3.1 Abstract  
In an attempt to identify gene expression changes induced by human 
polynucleotide phosphorylase (hPNPaseold-35) we performed genes expression analysis 
of HeLa cells in which hPNPaseold-35 was overexpressed and compared these changes 
to HO-1 melanoma cells in which stably knocked down hPNPaseold-35. We identified 90 
transcripts following this analysis which positively or negatively correlated with hPNPase 
expression and most of which were associated with cell communication, cell cycle and 
chromosomal organization gene ontology categories. Some of these genes were also 
identified in four TCGA (The Cancer Genome Atlas) datasets we screened, colon 
adenocarcinoma (COAD), skin cutaneous melanoma (SKCM), ovarian serous cyst 
adenocarcinoma (OV), and prostate adenocarcinoma (PRAD), with expressions 
correlating with hPNPaseold-35 as we identified in our microarray analysis. Further 
analysis comparing the gene expression changes between Ad.hPNPaseold-35 infected 
HO-1 melanoma cells and HeLa cells overexpressing hPNPaseold-35 under the control of 
a doxycycline-inducble promoter, revealed global changes in genes involved in cell 
cycle and mitosis. This study provides further evidence that hPNPaseold-35 is associated 
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with global changes in cell cycle-associated genes.     
3.2 Introduction 
Human polynucleotide phosphorylase, an evolutionarily conserved 3’-5’ 
exoribonuclease, has been implicated in numerous cellular functions over the past 
decade since its discovery as an upregulated transcript in terminally differentiated 
melanoma cells and senescent fibroblasts [17]. Some of the major findings relating to 
this interesting enzymatic protein revolve around its ability to cause growth suppression 
of cancer cells as a result of c-myc mRNA degradation and more recently due to its 
post-transcriptional regulation of miR-221 [48,49]. It is also implicated in the generation 
of reactive oxygen species leading to chronic inflammation, suggesting a probable role 
for this enzyme in senescence associated degenerative diseases [74,75]. Apart from 
this hPNPaseold-35 plays a major role in the maintenance of cellular homeostasis, 
imports RNA into the mitochondria, mediates mtRNA processing and is part of a 
complex that is responsible for mtRNA decay [44,47,50,76,87,88]. Although these 
findings are a major step forward in delineating the functional roles this enzyme plays in 
cellular physiology, not a lot is known about the molecular targets of hPNPaseold-35 from 
an enzymatic perspective apart from c-myc and miR-221 and its processing activities in 
the mitochondria.  
Thus, to further our quest in trying to unravel the molecular targets involved in the 
biological processes hPNPaseold-35 regulates which would ultimately help in the 
identification of therapeutic targets, we decided to perform gene expression analysis of 
melanoma cell lines following gain or loss of function of hPNPaseold-35. Pertaining to this, 
we provide extensive details in Chapter 2, where we have attempted to unravel the 
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global implications of hPNPaseold-35 deregulation using melanoma as a model system. 
We have been able to identify transcripts that may be direct or indirect targets of 
hPNPaseold-35, while also showing and reinforcing the fact that hPNPaseold-35 regulates 
mitochondrial homeostasis and cell cycle associated pathways.   
As an extension of Chapter 2 we wanted to explore the possibility of whether 
similar effects would be observed in a system other than melanoma. In order to do this 
we performed microarray analysis in HeLa cells to evaluate the gene expression 
changes occurring as a result of hPNPaseold-35 overexpression, which would help us 
answer whether the changes we observed in the HO-1 cells were a more global 
phenomana or a cell type specific effect. Also, to attain overexpression levels of 
hPNPaseold-35 that were more physiologically relevant we made use of a doxycycline-
inducible overexpression system. To identify hPNPaseold-35 induced or repressed genes, 
we overlapped these microarray results with the hPNPaseold-35 knockdown data we 
reported in Chapter 2. Secondly, we explored the TCGA database to identify in vivo 
tissue correlations of the genes we identified with hPNPaseold-35 expression levels which 
provides additional validation for our current findings. Finally, we also compared the 
gene expression changes occurring as a result of hPNPaseold-35 overexpression in HeLa 
cells and the Ad.hPNPaseold-35 infected HO-1 cells we described in Chapter 2 to 
understand the global implications of hPNPaseold-35 upregulation. This study provides 
further proof of the global impact of hPNPaseold-35 on cell cycle events and the identified 
targets provide us with additional information, which may be used for the recognition of 
possible therapeutic targets for hPNPaseold-35 associated diseases.   
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3.3 Materials and methods 
3.3.1 Establishing a conditional hPNPaseold-35old-35 over-expressing cell line 
The full-length cDNA of hPNPaseold-35old-35 with a C-terminal HA tag was cloned 
into a modified version of the Tet-On pTRIPZ vector (Open Biosystems, provided by Dr. 
Kristoffer Valerie) to permit inducible expression of the gene in the presence of 
doxycycline. HeLa-Tet-On cell lines were established by transfecting HeLa cells 
(Lipofectamine 2000, Invitrogen) with the pTRIPZ -hPNPaseold-35old-35 plasmid (sequence 
was verified before use) and stable clones were selected with the help of puromycin (2 
µg/ml) supplemented media. The expression of hPNPaseold-35old-35 in the different clones 
was tested after inducing with doxycycline by Western blotting analysis.  
3.3.2 MTT and colony formation assays 
Dox-inducible HeLa cell clones 5, 6, 7 and 27 were seeded in 96-well plates (in 
quadruplicates) at a density of 1000 cells per well and difference in cellular viability 
between the dox-induced and uninduced controls was monitored by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) staining over a period of 5 
days. The same cells were also seeded in 6-cm plates at a density of 1000 cells per 
plate and doxycycline was added. Colonies in the dox-treated and untreated plates 
(done in triplicates) were counted after 2 weeks by treating with Giemsa stain. Normal 
HeLa cells and pTRIPZ-RFP HeLa cells (with and without dox) were used as additional 
controls in both of the above experiments. 
3.3.3 Total RNA isolation for microarray analyses 
Total RNA from the hPNPaseold-35old-35 knockdown and control cell lines (HO-1 
melanoma cells stably expressing shRNA for hPNPaseold-35old-35 and scrambled control 
	  	   81	  
shRNA) and the hPNPaseold-35old-35 conditionally over-expressing doxycycline treated 
and untreated control cell lines (HeLa cells stably transfected with pTRIPZ-hPNPaseold-
35old-35 induced with doxycycline for 24 hrs and uninduced cells as control) was isolated 
from cell lysates in TRIZOL reagent (InvitrogenTM Life Technologies, Carlsbad, CA). 
Cell lysates were subjected to an automated extraction method using the MagMAX™-
96 for Microarrays Total RNA Isolation Kit (Ambion/InvitrogenTM Life Technologies, 
Carlsbad, CA) on the MagMAX™ Express Magnetic Particle Processor (Applied 
Biosystems/InvitrogenTM LifeTechnologies, Carlsbad, CA).  
3.3.4 Gene Expression Microarrays 
Gene expression profiles were ascertained using GeneChip® Human Genome 
U133A 2.0 (HG-U133A 2.0) arrays (Affymetrix, Santa Clara, CA) as previously 
described [100]. Every chip was scanned at a high resolution, with pixelations ranging 
from 2.5 µm down to 0.51 µm, by the Affymetrix GeneChip® Scanner 3000 according to 
the GeneChip® Expression Analysis Technical Manual procedures (Affymetrix, Santa 
Clara, CA). After scanning, the raw intensities for every probe were stored in electronic 
files (in .DAT and .CEL formats) by the GeneChip® Operating Software (GCOS) 
(Affymetrix, Santa Clara, CA). The overall quality of each array was assessed by 
monitoring the 3′/5′ ratios for a housekeeping gene (GAPDH) and the percentage of 
“Present” genes (%P); where arrays exhibiting GAPDH 3′/5′ < 3.0 and %P > 40% were 
considered good quality arrays. All experiments were done in biological triplicates.  
3.3.5 Statistical Analyses 
The Robust Multiarray Average method (RMA) was used for normalization and 
obtaining probe set expression summaries for the gene expression assays. These 
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values were then used to identify genes significantly altered among the different 
conditions (i.e., hPNPaseold-35old-35 up- and down-regulation), and analyzed for 
significance across replicate experiments with the help of TM4-MeV (MultiExperiment 
Viewer) analysis software by using a permutation method performed with the 
Significance Analysis of Microarray (SAM) program from Stanford University [Stanford, 
CA]. Once the program reported the list of ranked genes whose expression changed in 
the opposite direction in the two datasets, the “delta value” was adjusted to a stringent 
false discovery rate (FDR) of 5%. Cluster analysis was done using the Cluster and 
TreeView programs 4. Genes reported by SAM were analyzed by hierarchical clustering 
with average linkage grouping.  
In order to identify transcripts whose expression negatively or positively 
correlated with the expression of c-myc, we employed a Pearson correlation coefficient 
of 0.01 and statistical significance of the identified genes was set at p-value cutoff of 
0.05 using standard t-test. 
3.3.6 Enrichment analysis 
The Protein ANalysis THrough Evolutionary Relationships (PANTHER) resource 
was used to identify Gene Ontology (GO) categories and generate pie charts for the 
hPNPaseold-35 responsive genes (www.pantherdb.org) [123-125]. PANTHER can 
categorize genes based on their molecular functions, biological processes and protein 
classes with the help of available literature and evolutionary relationships.  
   Functional annotation cluster analysis was done using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) for the Gene ontology-based functional 
enrichment of the gene lists, using their respective gene symbols [126-128]. This kind of 
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analysis allows us to group functionally related genes together, which in turn provides a 
global view of altered biological networks.  
The MetaCore™ (GeneGo Inc. USA) bioinformatics software was used in order 
to gain a deeper understanding of the plausible molecular networks or biological 
pathways the hPNPaseold-35 responsive might be involved in [129,130]. The build 
network tool assigns pathway significance based upon the number of genes 
represented within a pathway and the direction of change.  
The comparison analysis tool in the IPA (Ingenuity Pathway Analysis) software 
was used to evaluate the common biological processes and canonical pathways 
between the doxycycline-inducible HeLa hPNPaseold-35 overexpression system and the 
Ad.hPNPaseold-35 infected HO-1 cells. 
3.3.7 Analysis of TCGA Genome-wide Expression Datasets 
The processed, Illumina Hi Seq 2000-generated TCGA  (The Cancer Genome 
Atlas) genome-wide expression datasets for colon adenocarcinoma (COAD), skin 
cutaneous melanoma (SKCM), OV (ovarian serous cystadenocarcinoma) and PRAD 
(prostate adenocarcinoma) were obtained through the UCSC Cancer Genomics 
Browser (https://genome-cancer.ucsc.edu/) (Goldman M et al, 2013).   The sample 
breakdown for each dataset is as follows: COAD (193 primary, tumors, 18 solid tissue 
normal), SKCM (241 metastatic, samples, 43 primary tumors), OV (262 primary tumors, 
4 recurrent tumors), PRAD (176 primary tumors, 44 solid tissue normals).  In addition, 
the UCSC pan cancer (PANCAN) dataset (Cline MS et al., 2013), which resulted from 
merging (and normalization) of all of the 22 TCGA genome wide expression (Illumina Hi 
Seq 2000) cancer cohorts (including COAD, OV, PRAD, and SKCM) with a combined 
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total of 6040 samples (4982 primary tumors, 271 metastatic, 27 recurrent tumors, 173 
peripheral blood, 587 solid tissue normals), was downloaded from the same website 
and subsequently analyzed.   The primary objective of the analyses was to examine the 
possible transcriptional correlations between hPNPase (PNPT1) and genes identified 
through the cell line-based experiments. Through the use of the Gene-E program 
(Broad Institute, Cambridge, MA) and the JMP 10 Pro statistical software (SAS, Cary, 
NC), the correlations between hPNPase expression levels and those of other genes of 
interest were examined by calculation of Pearson correlation coefficients and generation 
of heat maps.  
3.3.8 cDNA synthesis and quantitative real-time RT-PCR (qRT-PCR) 
Total RNA was harvested using the RNeasy purification kit (Qiagen). The quality 
and concentrations of isolated RNA samples were assessed using the NanoDrop 2000 
(Thermo Scientific). 2 µg of RNA was used in a total volume of 20 µl to synthesize 
cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) 
according to the manufacturer’s instructions. Real-time quantitative PCR was conducted 
using the ViiATM 7 Real-Time PCR System (Applied Biosystems) and performed in a 
total volume of 20 µl that contained the TaqMan Gene Expression Master Mix (Applied 
Biosystems), 1 µl of the cDNA template generated and the target-specific TaqMan Gene 
expression assays (Applied Biosystems) according to following cycle parameters: 95°C 
for 10 minutes followed by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. 
Each sample was run in triplicate using three biological replicates and normalized to the 
housekeeping gene GAPDH used as an internal control in each case. The ΔΔCt method 
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was used for comparing relative fold expression differences in the genes of interest 
between different test samples.  
3.3.9 Protein isolation and Western blot analysis 
    Cells were harvested by centrifugation, pellets washed in PBS and subsequently 
lysed in ice-cold 1X cell lysis buffer (Cell Signaling) supplemented with PhosSTOP 
Phosphatase Inhibitor Cocktail Tablets and complete Mini Protease Inhibitor Cocktail 
Tablets (Roche), followed by centrifugation at 13,000 rpm for 15 minutes at 4°C. The 
supernatant or whole cell lysate was collected in a fresh tube and protein concentration 
was measured using the Bio-Rad Protein Assay Dye Reagent Concentrate (BIO-RAD). 
30 µg of total cell lysate was mixed with SDS sample buffer and heated for 5 minutes at 
95°C. The proteins were separated by 8-10% SDS-PAGE gels and transferred onto 
nitrocellulose membranes and blocked using 5% non-fat milk supplemented with 1% 
bovine serum albumin (BSA) in TBS-T for 1 hour. After washing three times with TBS-T 
for 10 minutes each, the membranes were incubated with primary antibodies overnight 
at 4°C. The primary antibodies used were anti-HA (mouse, 1:1000), anti-hPNPaseold-
35old-35 (chicken; 1:5000), anti-EF1α (mouse, 1:1000). The next day membranes were 
washed as before and incubated with the relevant horseradish-peroxidase conjugated 
secondary antibodies for 1 hour at room temperature. After washing three times with 
TBS-T for 10 minutes each, the proteins were detected using ECL Western Blotting 
detection reagent (GE Healthcare Life Sciences) and exposed to X-ray film.  
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3.4 Results 
3.4.1 Establishing a doxycycline-inducible hPNPaseold-35 over-expression system 
The stable clones selected were evaluated for hPNPaseold-35 expression by 
Western blotting. Figure 3.1 represents the results obtained for clones 5, 6, 7 and 27, 
where protein expression was checked at different time points and with increasing 
doses of doxycycline separately. Clone 5 showed better responses to different doses 
and temporal expression than the other clones and was thus selected for microarray 
analysis. 
Previous studies have established a role for hPNPaseold-35 in the processes of 
growth inhibition, where it was overexpressed by means of a replication-deficient 
adenovirus. In order to corroborate these results in the present overexpression system, 
MTT cell viability assays and colony formation assays were performed. Doxycycline 
treated clones 5 and 6 showed a slower growth rate (~40% less) as compared to their 
untreated counterparts as measured by MTT reagent (Figure 3.2) and reduced number 
of colonies (~50% less colonies) (Figure 3.3), when hPNPaseold-35 was overexpressed 
as compared to clones 7 and 27 (Figures 3.3 and 3.4). The control HeLa cells and the 
empty pTRIPZ vector HeLa clones did not show any significant difference in growth with 
or without the presence of doxycycline (Figure 3.4).  
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 Fig. 3.1. Western blots showing hPNPaseold-35 overexpression in doxycycline-
inducible stable HeLa cells in a time and dose-dependent manner.	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Fig. 3.2. MTT cell viability assays. hPNPaseold-35 overexpression in doxycycline-
inducible stable HeLa clones (A-D) shows a reduction in cellular growth over a period 
of 5 days as determined by MTT assay. Error bars represent mean ± standard error 
of one experiment done in quintuplicate, statistical significance determined by two-
tailed student’s t-test, *P<0.05.	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Fig. 3.3. Colony formation assays. hPNPaseold-35 overexpression in doxycycline-inducible 
stable HeLa clones (A-D) shows a reduction in cellular growth as observed by reduced 
number of stained colonies.  	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3.4.2 Identification of hPNPaseold-35 responsive genes 
To explore the effects of hPNPaseold-35 on the global regulation of gene 
expression, we conducted cDNA microarray analyses using HeLa cells stably 
transfected with a doxycycline-inducible hPNPaseold-35 expression vector to attain 
physiologically relevant levels of hPNPaseold-35 overexpression and HO-1 melanoma 
cells in which hPNPaseold-35 expression was stably knocked down using shRNA 
(described in detail in Chapter 2). Unsupervised hierarchical cluster analyses revealed 
that the six HeLa and six HO-1 arrays cluster with their respective class (Figure 3.5), 
which implies that the microarray results are robust and can differentiate between the 
cell types.  
Fig. 3.4. Colony formation and MTT assays to determine cell viability of control HeLa 
and HeLa-RFP cells. Error bars represent mean ± standard error of one experiment done in 
quintuplicate.	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A comparative analysis between the two datasets with the help of TM4-MeV 
analysis software allowed the identification of 90 transcripts whose expression was 
inversely affected in both datasets significantly. Out of these 90 transcripts, the 
expression of 62 transcripts correlated positively with hPNPaseold-35 (Figure 3.6.A) and 
the expression of 28 transcripts anti-correlated or negatively correlated with hPNPaseold-
35 (Figure 3.6.B). Some genes are represented on the microarray by multiple probe sets 
and thus were identified more than once (as evident in Figure 3.6). Apart from providing 
an additional internal control, this finding also increases confidence in the identification 
of certain genes as being responsive to hPNPaseold-35 levels.  
Fig. 3.5. Unsupervised hierarchical cluster analysis. 
Unsupervised cluster dendrogram using centered 
correlation and average linkage, based on 22,227 probe 
sets for the 12-array dataset.	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Fig. 3.6. Comparison of hPNPaseold-35-induced changes in gene expression in 
HO-1 and HeLa cells. Hierarchical clustering of hPNPaseold-35 positively (A) and 
negatively (B) correlating genes as identified by microarray analysis. 
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3.4.3 Functional categorization of hPNPaseold-35 responsive genes 
The hPNPaseold-35 responsive genes were arranged into various biological 
processes, molecular functions and protein classes using the Gene Ontology (GO) 
categories available through the PANTHER database and its tools. These functional 
categories are represented in Figure 3.7 where the pie charts include categories with at 
least five genes. GO analysis of the biological processes (12 identified in total) involving 
the hPNPaseold-35 responsive genes we report here showed that the major categories in 
this case belonged to cellular (18.5%) and metabolic processes (17.6%). The genes 
involved in cellular processes belonged majorly to cell communication (36.4%), cell 
cycle (19.5%) and cell adhesion (16.9%) sub-categories.  
          
 Fig. 3.7. Gene Ontology (GO) terms for PNPase responsive genes. GO 
analysis corresponding to Biological process	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The genes involved with metabolic processes belonged majorly to primary 
metabolic processes (86%), which in turn comprised of nucleic acid (38.3%), protein 
(34%), lipid (14.9%), amino acid (8.5%) and carbohydrate metabolism (4.3%). The 
major molecular functions the hPNPaseold-35 responsive genes were attributed to were 
catalytic activity (29.2%, mainly hydrolases, oxidoreductases and transferases) and 
binding (28.3%, mainly protein and nucleic acid binding) (Figure 3.8).  
 
 
 
Fig. 3.8. Gene Ontology (GO) terms for PNPase responsive genes. GO analysis 
corresponding to Molecular functions. 	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The top protein function categories the hPNPaseold-35 responsive genes belonged 
to were; hydrolases (12.4%), nucleic acid binding (10%) and receptors (8.5%) (Figure 
3.9).     
 
Functional annotation clustering by DAVID resulted in the identification of 32 clusters of 
related genes, with the highest enrichment score being 1.91. The most significantly 
enriched gene clusters along with their GO categories are represented in Figures 3.10-
3.12 and relate to chromosomal organization (score=1.91, 18 genes: HIST1H2BK, 
HIST1H3H, H2BFS, CENPA, TSPYL4, CENPE, TOP2A, HMG20B, ERCC6L, 
SYNCRIP, KIF14, MKI67, ZNF226, DNASE1L1, POLQ, KIF15, CDKN1A, PLK4) (Figure 
3.10), signaling molecules (score=1.67, 32 genes: AK2, GLRX, UQCRFS1, TMEM2, 
Fig. 3.9. Gene Ontology (GO) terms for PNPase responsive genes corresponding to 
PANTHER Protein class identified by PANTHER classification system 
(http://www.pantherdb.org/).	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TMEM149, SLC1A3, SDC4, GKN1, LYPD1, NEU1, KIAA1644, ANTXR1, SERPINI1, 
CRIM1, CD164, EMR2, ROR2, LRP10, DNASE1L1, CD55, IL10RB, SMPDL3A, 
COL9A3, STC2, LUM, SRGN, SMPD1, NRP1, DDR1, DKK3, SFRP1, IGFBP3) (Figure 
3.11) and cell cycle (score=1.37, 15 genes: CENPE, KIF11, KIF15, KIF3C, KIF14, 
ERCC6L, MKI67, CENPA, CDKN1A, PLK4, TOP2A, LLGL2, HMG20B, DUSP1, AK2) 
(Figure 3.12).   
 
Fig. 3.10. Functional annotation of genes significantly regulated by hPNPaseold-
35 represented as enrichment clusters generated by the DAVID analysis 
software. Cluster of 18 genes which were grouped together based on their 
involvement in chromosomal organization and related functions. Green - 
corresponding gene-term association positively reported in DAVID; black - 
corresponding gene-term association not reported yet in DAVID. 
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 Fig. 3.11. Functional annotation of genes significantly regulated by 
hPNPaseold-35 represented as enrichment clusters generated by the DAVID 
analysis software. Cluster of 32 signaling molecules and cellular receptors. 
Green - corresponding gene-term association positively reported in DAVID; 
black - corresponding gene-term association not reported yet in DAVID. 
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MetaCore™ (GeneGo Inc. USA) analysis of the hPNPaseold-35 responsive genes 
resulted in the identification a number of gene interaction networks, two of which are 
represented in Figure 3.13 and 3.14.  The first network (Figure 3.13) includes 14 genes 
(CENPA, CENPE, TOP2A, PLK4, ERCC6L, DDIT4, SFRP1, CRIM1, ZC3HAV1, MVP, 
DKK3, FAM134B, LOH11CR2A, and MAGED2) from the list of hPNPaseold-35 
responsive genes identified and p53 seems to be a critical player in this signaling 
cascade. The second network (Figure 3.14) includes 11 (CENPA, STC2, IGFBP3, 
DUSP1, ZC3HAV1, PDZK1, SDC4, NRP1, CDKN1A, RGL1, TOP2A) of the hPNPaseold-
Fig. 3.12. Functional annotation of genes significantly regulated by hPNPaseold-35 
represented as enrichment clusters generated by the DAVID analysis software. 
Cluster of 15 genes grouped together based on their link to cell cycle-associated functions. 
Green - corresponding gene-term association positively reported in DAVID; black - 
corresponding gene-term association not reported yet in DAVID. 
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35 responsive genes, with STAT1 and p21 appearing as major regulatory proteins in this 
pathway.  
 
 
 
Fig. 3.13. Pathway analysis of hPNPaseold-35 responsive genes.  Network 
associated with mitosis and involves 14 of our reported hPNPaseold-35 responsive 
genes. 	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Fig. 3.14. Pathway analysis of hPNPaseold-35 responsive genes.  Network  
associated with p21 signaling and involves 11 of our reported hPNPaseold-35 
responsive genes.  
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Representative genes in the two networks such as CENPA and CENPE are validated 
by qRT-PCR, which are downregulated in response to hPNPaseold-35 overexpression 
(Figures 3.15 and 3.16). hPNPaseold-35 stable knockdown in HO-1 and WM35 melanoma 
cells resulted in a ~1.2 fold increase in SYNCRIP and a ~1.2-1.6 fold increase in 
CENPA potential direct target levels as determined by qRT-PCR (Figure 3.15A-B). 
Transient knockdown of hPNPaseold-35 also resulted in a 1.4 fold increase in SYNCRIP 
and a ~2 fold increase in CENPA RNA levels in HeLa cells (Figure 3.15C), validating 
that this is not a cell line specific effect, nor an indirect effect due to stable knockdown. 
Plasmid mediated overexpression of hPNPaseold-35 in HO-1 melanoma cells resulted in 
a 20% and 30% reduction in SYNCRIP and CENPA RNA levels respectively (Figure 
3.15D). Figure 3.16A shows a graphical representation of the fold decrease in the RNA 
levels of CENPA, CENPE and MKI67 following adenoviral mediated overexpression of 
hPNPaseold-35 in HO-1 and WM35 melanoma cells in comparison to their respective fold 
changes as obtained in the microarray results. Adenoviral mediated overexpression of 
hPNPaseold-35 in three different melanoma cell lines (HO-1, WM35 and MeWo) all 
resulted in ~40% reduction in CENPA levels (Figure 3.16B). 
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Fig. 3.15. Real-time PCR validation of genes identified by microarray analysis. (A) 
hPNPaseold-35 –stable knockdown HO-1cells, (B) hPNPaseold-35 –stable knockdown WM35 
cells, (C) HeLa cells transiently transfected with siRNA against hPNPaseold-35 and (D) HO-1 
cells transfected with pcDNA3.1- hPNPaseold-35. Error bars represent mean ± S.E. of three 
independent experiments done in triplicate, statistical significance was determined by a one-
way analysis of variance followed by Dunnett’s multiple comparison test and a two-tailed 
student’s t-test, *P<0.05, **P<0.01, ***P<0.001.	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Fig. 3.16. Real-time PCR validation of genes identified by microarray analysis 
following Ad.hPNPaseold-35 –mediated overexpression. Error bars represent 
mean ± S.E. of three replicate experiments. Statistical significance was determined 
by two-tailed student’s t-test, *P<0.05, **P<0.01.	  
<0.01	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3.4.4 TCGA correlations of hPNPaseold-35 responsive genes 
The Cancer genome atlas (TCGA) database is an enormous repository of gene 
expression data from various normal and cancer tissue types. In order to evaluate the in 
vivo implications of the hPNPaseold-35	   responsive genes we identified, we decided to 
investigate their potential correlation with hPNPaseold-35	   in various TCGA datasets. The 
genes identified as positively or negatively correlating with hPNPaseold-35	  expression in 
different cancer types are represented in the heat maps shown in Figure 3.17. Prior to 
heat map generation, each gene expression value (at log, base 2 scale) for every 
sample was transformed by subtracting the average expression across all samples in a 
given dataset. As shown in Figure 3.17, the samples in the TCGA OV, COAD, SKCM, 
and PRAD cohorts were arranged in order of increasing hPNPaseold-35	  expression level, 
going from green to red. One gene that stood out is DUSP1. As the hPNPaseold-35	  
expression of OV, COAD, SKCM, and PRAD samples increased, DUSP1 level 
decreased (also indicated by negative Pearson correlation coefficients). The Pearson 
correlation coefficient (r) between hPNPaseold-35	  and DUSP1 registered at -0.362.  This r 
value was 221st lowest (99th percentile) among the 20500 genes whose expression 
was related to hPNPaseold-35. As the heat maps indicate, opposite expression trends 
(compared to hPNPaseold-35) were observed for the genes KI1644  (OV, COAD, PRAD), 
ADARB1 (OV, COAD), HMG20B (COAD), IGFBP3 (COAD, PRAD), DDIT4 (COAD, 
PRAD), EMR2 (COAD, SKCM), SLC1A3 (COAD, PRAD), and DHRS2 (PRAD).  In 
contrast, the expression levels of the genes GLS (COAD, SKCM, PRAD), LACTB2 
(COAD, SKCM, PRAD), MRPS12 (COAD), NEU1 (COAD), CD164 (SKCM), FKBP1B 
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(OV), KIF3C (OV), and SFT2D2 (PRAD) exhibited positive correlation with hPNPaseold-
35. 
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Fig. 3.17. Heat maps representing correlations of hPNPaseold-35 responsive genes with 
hPNPaseold-35 in different tumor types identified using TCGA datasets. (A) hPNPaseold-35 
positively and (B) hPNPaseold-35 negatively correlating genes in (i) colon adenocarcinoma 
(COAD), (ii) ovarian serous cyst adenocarcinoma (OV), (iii) prostate adenocarcinoma (PRAD), 
and (iv) skin cutaneous melanoma (SKCM).	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3.4.5 Identification of Myc-correlating genes 
c-MYC mRNA has been previously shown to be regulated by hPNPaseold-35 at 
the post-transcriptional level. Since c-myc is an essential cell cycle regulator and also a 
transcription factor implicated in the regulation of expression of numerous genes, we 
were interested to identify if genes differentially regulated by hPNPaseold-35 following its 
gain or loss of function were in any way under c-myc transcriptional control. Thus, in 
order to dissect the potential role of myc in the regulation of hPNPaseold-35 responsive 
genes, we identified genes in our two datasets (hPNPaseold-35 knockdown and 
overexpression) whose expression correlated with c-myc expression. 31 genes were 
identified with expression negatively correlating with c-myc and 29 with expression 
positively correlating with c-myc. We further grouped the 60 c-myc correlating genes 
into biological categories using the functional annotation cluster analysis tool in DAVID, 
which resulted in the identification of 26 gene enrichment clusters with the highest 
enrichment score being 2.02. Some of the functional categories identified were 
apoptosis (Figure 3.18), DNA repair (Figure 3.19), cytoskeleton (Figure 3.21) and 
mRNA processing (Figure 3.22). 11 of c-myc correlating genes identified were also 
among the hPNPaseold-35 regulated genes we report here. Of these eleven genes, the 
expression of DHRS2, LSM5, STC2, TOP2A positively correlated with c-myc and 
IL10RB, LOH11CR2A, MLLT11, MRPS12, NEU1, SMPD1, UQCRFS1 negatively 
correlated with c-myc. 
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Fig. 3.18.  Cluster analysis of functional enrichments for c-Myc correlating 
genes. Cluster of 13 genes involved in apoptosis. Green - corresponding gene-
term association positively reported in DAVID; black - corresponding gene-term 
association not reported yet in DAVID. 
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Fig. 3.19.  Cluster analysis of functional enrichments for c-Myc 
correlating genes. Cluster of 16 genes involved in cytoskeleton 
associated functions. Green - corresponding gene-term association 
positively reported in DAVID; black - corresponding gene-term 
association not reported yet in DAVID. 
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Fig. 3.20.  Cluster analysis of functional enrichments for c-Myc correlating 
genes. Cluster of 13 genes involved in DNA repair. Green - corresponding 
gene-term association positively reported in DAVID; black - corresponding 
gene-term association not reported yet in DAVID. 
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3.4.6 hPNPaseold-35 overexpression in HO-1 and HeLa cells causes global changes 
in cell cycle-associated genes 
A comparison between the transcriptome analysis of HeLa cells in which 
hPNPaseold-35 was overexpressed by means of a doxycycline-inducible system and 
Ad.hPNPaseold-35old-35 infected HO-1 cells revealed 105 differentially regulated genes 
(FDR<5%) common among both analyses, some of which are represented in Figure 
3.22. 
Fig. 3.21.  Cluster analysis of functional enrichments for c-Myc correlating 
genes. Cluster of 10 genes involved in mRNA processing. Green - corresponding 
gene-term association positively reported in DAVID; black - corresponding gene-
term association not reported yet in DAVID. 
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Overall, there were 31 upregulated and 74 downregulated overlapping transcripts 
in both studies. In order to classify these genes into biological categories, we made use 
of the ToppGene suite of web applications (Table 3.1). The most significant 
overrepresented categories were cell cycle, mitosis and DNA metabolism associated 
functions.  
 
 
 
Fig. 3.22. Genes differentially regulated in response to hPNPaseold-35 overexpression as 
identified by microarray analysis in HO-1 and HeLa cells. 
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Table 3.1. Functional annotation of genes differentially regulated in response to 
hPNPaseold-35 overexpression by ToppGene suite. 
Functional category Source p-value no. of genes 
 RNA binding  GO: Molecular Function 1.90E-02 16/857 
 Cell Cycle phase  GO: Biological Process 5.81E-11 30/864 
 Mitotic Cell Cycle  GO: Biological Process 1.31E-08 26/785 
 DNA metabolic process  GO: Biological Process 9.19E-07 25/879 
 Chromosome  GO: Cellular Component 3.89E-08 21/641 
 Nucleoplasm  GO: Cellular Component 6.32E-06 28/1483 
 Genes involved in cell cycle, 
Mitotic pathway  MSigDB 2.61E-04 14/306 
    
 
We also compared the top biological functions (Figure 3.23) and canonical 
pathways (Figure 3.24) associated with all the differentially regulated transcripts in both 
systems to further understand the global implications of hPNPaseold-35 overexpression. 
The most significant biological processes identified by IPA (Ingenuity Pathway Analysis) 
were majorly associated with cell cycle-associated functions. More interestingly, most of 
the canonical pathways identified in both overexpression systems were also associated 
with cell cycle regulatory functions.  
 
 
	  	   114	  
        
 
 
Fig. 3.23. Biological functions identified by IPA corresponding to genes 
differentially regulated in response to hPNPaseold-35 overexpression. Hela 
pnp = dox-inducible hPNPaseold-35 overexpression, mel adpnp = 
Ad.hPNPaseold-35-mediated overexpression. 
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 Fig. 3.24. Canonical Pathways identified by IPA corresponding to genes 
differentially regulated in response to hPNPaseold-35 overexpression. Hela pnp 
= dox-inducible hPNPaseold-35 overexpression, mel adpnp = Ad.hPNPaseold-35-
mediated overexpression. 
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3.5 Discussion 
In the present study, we have attempted to further unravel the global gene 
expression patterns involved with hPNPaseold-35 gain or loss-of-function. We compared 
the gene expression changes resulting from hPNPaseold-35 knockdown and 
overexpression in two different cells lines and identified overlapping genes. In the 
current analysis we identified 62 hPNPaseold-35 induced and 28 hPNPaseold-35 repressed 
genes. Gene ontology analysis of these hPNPaseold-35 induced and repressed 
transcripts revealed that a number of them are involved in cell cycle, chromosomal 
organization and cellular signaling. We obtained similar evidence in Chapter 2, where 
we showed that overexpression of hPNPaseold-35 cause’s global deregulation in cell 
cycle-associated genes. Our overlapping analysis helped us to identify genes like 
KIF3C [133] and CDKN1A [135], which are transcripts upregulated during growth arrest, 
also induced by hPNPaseold-35. Also, a number of genes involved in cellular growth and 
proliferation were found to be downregulated like CENPA, CENPE, PLK4, TO2PA, and 
POLQ, transcripts repressed by hPNPaseold-35. Further support for this premise was 
obtained when we attempted to identify any particular network the hPNPaseold-35 
correlating genes interacted in. We were able to identify two networks relating to 
mitosis/cell cycle and p21 (a known regulator of growth arrest and cellular senescence) 
regulation. From this it can be concluded that hPNPaseold-35 plays a role in cell cycle-
associated functions, but future studies would be required in order to gain more 
mechanistic insights of this regulation.         
Interestingly, some of these genes are common between the overlapping genes 
we identified in Chapter 2, MKI67 (a cellular proliferation marker) and CENPE 
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(Centromere protein E), which are repressed or negatively correlate with hPNPaseold-35 
expression and are important for cellular proliferation. In a way this is a further validation 
of the fact that the expression of these transcripts is in some way regulated by 
hPNPaseold-35. Another centomeric protein, which is also repressed, CENPA 
(Centromere protein A), was identified in this analysis. This finding could be of potential 
importance, as CENPA is reported to be a prognostic marker for ER-positive breast 
cancer [134] and lung adenocarcinoma [135] and could be a potential therapeutic target 
for treatment of cancer and other hPNPaseold-35 associated diseases. Future studies 
would be required to further explore this avenue. More interestingly, some of the 
hPNPaseold-35 correlated genes we report here were also found to correlate with 
hPNPaseold-35 expression in four TCGA normal and cancer tissue datasets we analyzed. 
Some of the transcripts identified may provide promising therapeutic leads in terms of 
treatment options for certain cancers while harnessing on hPNPaseold-35’s anti-
proliferative properties. Among these candidates are DUSP1, implicated in promotion of 
angiogenesis and metastasis of non-small-cell-lung cancer [136]; ADARB1, reported to 
be upregulated in numerous carcinomas [137-139]; EMR2, associated with poor 
prognosis in glioblastoma [140]. Although identification of these transcripts provides 
valuable future options for treatment of cancer and possible other diseases, the 
mechanism of hPNPaseold-35 regulation of these genes would need to be elucidated, i.e. 
are they directly degraded by hPNPaseold-35 (hPNPaseold-35 repressed genes) or do 
specific miRNAs control their expression which in turn hPNPaseold-35 regulates 
(hPNPaseold-35 induced genes).   
c-myc is a transcription factor involved in the regulation of numerous cellular 
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processes including but not restricted to apoptosis, cell cycle and metabolism, and most 
of the c-myc correlated genes we report here are associated with apoptosis, cell cycle, 
mRNA processing and DNA repair gene ontology categories. c-myc mRNA is also 
targeted by hPNPaseold-35 for exoribonucleolytic degradation, thus arises the complexity 
in our analyses of hPNPaseold-35 regulated gene expression changes. To this end we 
performed our microarray analyses at an early timepoint of 24 hrs following hPNPaseold-
35 overexpression, before c-myc levels started to deplete, but a small change of -1.4 fold 
was still evident in our microarray analyses following hPNPaseold-35 overexpression. 
Thus, we wanted to confirm if there were transcripts we identified as being hPNPaseold-
35 regulated that were also c-myc target genes. A search of the Myc target gene 
database (http://www.myccancergene.org) involving the 11 c-myc correlated/ 
hPNPaseold-35 responsive transcripts did not reveal any report of the direct regulation of 
these genes by c-myc transcription factor. Thus, at this time we cannot claim that the 
expression correlation of these transcripts with c-myc means that they are its targets. 
Future studies involving a search of c-myc binding sites in the promoter region of these 
transcripts may provide concrete information regarding this premise. Until then it would 
be safe to proclaim that gene expression changes induced by hPNPaseold-35 may 
involve numerous other regulatory factors causing global changes in cell cycle-
associated functions, apart from hPNPaseold-35’s direct degradation of mRNA and 
miRNA species.  
Finally, we compared the gene expression profiles of two different cell lines in 
which we overexpressed hPNPaseold-35 using two different mechanisms, a doxycycline-
inducible expression vector and an adenoviral vector. We not only observed 105 
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overlapping genes between both systems, but interestingly almost all these genes were 
associated with cell cycle, mitosis and chromosomal functions as identified by gene 
ontology categories. Apart from the overlapping genes, comparative pathway analysis 
of both the hPNPaseold-35 overexpression datasets revealed that the most significant 
affected pathways were related to cellular growth and proliferation. Since there was 
such a strong correlation of this gene list with cell cycle associated functions we wanted 
to evaluate whether any of these genes were targets of c-myc transcription activation or 
repression. A search for these genes in the c-myc target database mentioned earlier 
revealed that 28 of these genes were predicted targets of c-myc. Out of these 28 genes, 
four of the downregulated genes (E2F3, PTMA, DDX18 and TFRC) were also identified 
by ToppGene suite as validated targets of c-myc transcriptional activation (Table 1). 
Thus, at this time we can say that overexpression of hPNPaseold-35 may be associated 
with global regulation of cell cycle associated functions, as evidence is provided by the 
global deregulation of numerous genes involved in these events, although some of 
these changes could be associated with c-myc downregulation. In the event of 
hPNPaseold-35 overexpression, upregulation of pro-apoptotic molecules like FAS and 
downregulation of genes essential for cellular proliferation like E2F3, MCM4, MCM7 and 
EIF4G1 may tip the balance towards growth arrest. Whether hPNPaseold-35 directly 
degrades these transcripts (in vitro degradation assays would provide the ultimate proof 
for this hypothesis) or whether these are downstream events of a few preliminary events 
(like downregulation of c-myc eventually resulting in the cascade of events leading to 
growth inhibition) remains to be answered in the future studies performed in a c-myc-
null background.          
	  	   120	  
        
 
 
 
CHAPTER FOUR 
 
 
 
Analysis of sequence specificity for degradation by hPNPaseold-35 
 
 
 
4.1 Abstract 
Previous studies have established that c-myc mRNA is a direct degradation 
target of hPNPaseold-35. Over-expression of c-myc devoid its 3’UTR partially but not 
completely protects HO-1 cells from the growth-inhibitory effects of Ad.hPNPaseold-35 
infection. Other RNA species like c-jun and GADD34 are not degraded, suggesting that 
c-myc mRNA is a very specific target of hPNPaseold-35 degradation.  This may be due to 
the presence of specific sequence or secondary structural elements in the 3’UTR of c-
myc mRNA. The primary aim of this study is to address this question. 
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4.2 Introduction 
One of the molecular mechanisms elucidated responsible for the growth 
inhibitory properties of hPNPaseold-35 in cancer cells was found to be selective 
degradation of c-myc mRNA [48]. This has been proven by in vitro mRNA degradation 
assays also, where hPNPaseold-35 could specifically degrade c-myc mRNA, but not other 
mRNAs such as c-jun, GAPDH or GADD34 [29,48]. Specific RNA cis elements have 
been identified which affect the stability and/or translation of given subsets of mRNAs. 
Within the 3’UTR, the most commonly found cis elements determinants of mRNA 
turnover and translation are AU rich elements (AREs). The 3’UTR of c-myc mRNA has 
four such instability elements. It would be important to understand whether the presence 
of these ARE elements provides a specific sequence identification element or 
secondary structure that allows its degradation by hPNPaseold-35. Also, further 
sequence/secondary structure homology searches identifying similar mRNA species 
would be helpful in finding other hPNPaseold-35 target genes. 
4.3 Materials and Methods 
4.3.1 Construction of c-myc 3’UTR deletion mutants 
 
In order to evaluate the importance of each of the four AU rich elements in the 
3’UTR of c-myc mRNA and the role they may play in degradation by hPNPaseold-35, five 
sequential deletion constructs including the coding sequence and parts of the 3’UTR of 
c-myc were constructed (M1-M5). The specific 3’UTR deletion fragments were PCR 
amplified with specific primers using a human cDNA clone (ORIGENE) as template and 
subcloned into pGEM-Teasy vector (Promega). Subsequently, the fragments were 
digested with the help of EcoRI and XbaI restriction endonucleases and religated into 
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pcDNA 3.1/Hygro (+) expression vector. The sequences of all the constructs were 
verified before transfection. A diagrammatic representation of the deletion constructs 
M1-M5 is provided in Figure 4.1. 
 
 
4.3.2 Colony Formation Assays 
HO-1 cells were plated at a density of 2 x 105 cells/6-cm dish and 24 h later were 
transfected with 4 µg of either empty vector or plasmids M1-M5 using LipofectamineTM 
2000 (Invitrogen) transfection reagent according to the protocol from the manufacturer. 
After 36 h, the cells were infected with Ad.Vec or Ad.hPNPaseold-35 at a multiplicity of 
infection (m.o.i.) of 5000vp/cell; 6 h later, the cells were trypsinized and counted and 103 
cells were plated in 6-cm dishes in triplicate. Colonies were visualized by Giemsa 
staining and counted after 3 weeks.  
 
 
Fig. 4.1. Schematic representation of c-myc 3’UTR deletion constructs. 
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4.4 Results and Discussion 
Previous studies have shown that c-myc mRNA is a direct degradation target of 
hPNPaseold-35  [29,48,60], which is also one of the molecular mechanisms involved in 
hPNPaseold-35 mediated growth arrest. The specificity of this degradative effect lies in the 
3’UTR sequence of c-myc mRNA as shown by rescue experiments in which growth 
inhibition caused by Ad.hPNPaseold-35 infection could partially be rescued by 
overexpression c-myc devoid its 3’UTR [48]. As an extension of this interesting finding, 
3’UTR deletion mutants of c-myc were generated (Figure 4.2) to identify any specific  
	  
Fig. 4.2. Schematic representation of the cloning strategy used for the 
generation of the c-myc 3’UTR deletion constructs. 
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regions in the 3’UTR of c-myc mRNA that could be required for degradation by 
hPNPaseold-35. In order to evaluate this hypothesis, HO-1 cells were transfected with the 
five 3’UTR deletion constructs (M1-M5), infected with Ad.hPNPaseold-35 and the growth 
of cells was analyzed by colony formation assays after a period of 3 weeks (Figure 4.3). 
We observed that growth suppression caused by adenoviral-mediated hPNPaseold-35 
overexpression could be partially rescued by c-myc-3’UTR deletion constructs M1 
(28%, offers most protection as it is completed devoid of the 3’UTR), M2 (23%), and M3 
(17%) (Figure 4.4). Transfection with M4 resulted in >80% growth inhibition in 
conjunction with Ad.hPNPaseold-35 infection and M5 transfection resulted in only a ~10% 
rescue in growth followed by Ad.hPNPaseold-35 infection as compared to constructs M1-
M3, as shown in Figure 4.4. Based on these preliminary results we can presume that 
the region between 1562 and 1787bps (sequence present in constructs M4, M5 and 
deleted from constructs M1-M3) in the 3’UTR sequence of c-myc could possess 
recognition sequences or secondary structure elements necessary for hPNPaseold-35 
mediated degradation thus eliminating the growth protection rendered by constructs M1-
M3 (which do not possess the specific sequence region and are protected from 
hPNPaseold-35 degradation). Also, since M5, which has the complete 3’ UTR, provided 
more protection than M4 (which has region 1639-1787 deleted), it can be presumed that 
the specificity of degradation by hPNPaseold-35 is most likely dependent on secondary 
structural elements rather than primary sequence alone. These results would need to be 
further validated as although done in technical triplicates, these results are based on 
one biological experiment. Future experiments involving in vitro transcription of these 
deletion fragments followed by hPNPaseold-35 in vitro degradation assays would need to 
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be performed to analyze whether fragments M1-M3 are indeed protected from 
hPNPaseold-35 degradation and whether fragments M4, M5 are degraded by hPNPaseold-
35.   
 
 
 
 
Fig. 4.3. Growth rescue experiment. HO-1 cells were plated at a density of 2 x 105 
cells/6-cm dish and 24 h later were transfected with 4 µg of either empty vector or c-
myc 3’UTR deletion constructs M1-M5. After 36 h, the cells were infected with 
Ad.Vec or Ad.hPNPaseold-35 at a multiplicity of infection (m.o.i.) of 5000vp/cell; 6 h 
later, the cells were trypsinized and counted and 103 cells were plated in 6-cm dishes 
in triplicate. Colonies were visualized by Giemsa staining and counted after 3 weeks.  
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Fig. 4.4. Graphical representation of colony numbers as described in 
Fig. 4.3. The data represent mean ± standard error of one experiment done 
in triplicate, statistical significance was determined by two-tailed student’s t-
test, *P<0.05. 
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CHAPTER FIVE  
 
 
 
Evolutionary dynamics of Polynucleotide phosphorylases 
Part of the work presented in this chapter has been submitted for publication in 
Molecular Phylogenetics and Evolution (2013).  
 
5.1 Abstract 
Polynucleotide phosphorylase (PNPase) is an evolutionarily conserved 3’→5’ 
phosphate-dependent exoribonucease belonging to the PDX family of proteins. It 
consists of two catalytic RNase PH domains (PNP1 and PNP2), an α-helical domain 
and two RNA-binding domains. The PNP1 and PNP2 domain share substantial 
sequence and structural homology with RNase PH (RPH), which is another PDX family 
member found in all the three major kingdoms of life, suggesting that these three 
domains originated from a common ancestor. Phylogenetic analysis (based on the 
PNPase /RNase PH sequence information for 43 vertebrate taxa) shows that PNP2 and 
RPH are sister taxa which arose through duplication of the ancestral PNP1 domain. 
Also, all three domains (PNP1, PNP2 and RPH), along with the KH and S1 domains 
have undergone significant and directional sequence change, as determined by branch 
and site-specific dN/dS analyses. In general, codons that show dN/dS ratios that are 
significantly greater than 1.0 are outside the ordered regions (α-helices and β-sheets) of 
these protein domains. In addition, sites that have been selected for mutagenesis in 
	  	   128	  
these proteins lie embedded in regions where there is a preponderance of codons with 
dN/dS values that are not significantly different from 0.0.  Overall, this report is an 
attempt to further our understanding of the evolutionary history of these three protein 
domains, and define the evolutionary events that led to their refinement in the vertebrate 
lineage leading to mammals.   
5.2 Introduction 
RNA metabolism plays a significant role in the post-transcriptional control of gene 
expression in both prokaryotic and eukaryotic organisms [12]. Key players involved in 
the decay and processing of various RNA species are a special class of enzymatic 
proteins called ribonucleases (RNases) [37,141]. Based on their degradative functions, 
RNases are divided into endo- and exo-ribonucleases [13,93]. One such 
exoribonuclease is polynucleotide phosphorylase (PNPase), which is an ancient 
enzyme that has been evolutionarily conserved in all the kingdoms of life, although it is 
absent in Archaea and certain single cell eukaryotes [91]. Functionally, it is a 3’→5’ 
phosphorolytic exoribonuclease belonging to the PDX family of proteins [4,14]. The PDX 
family includes RNase PH, another phosphate-dependent exoribonuclease. Considered 
the simplest member of the PDX family, RNase PH was first identified in E.coli [28,142], 
and its orthologues are found in all kingdoms [91]. The main difference between RNase 
PH and PNPase is that in vivo, RNase PH is involved in the processing of tRNA 
precursors and in the digestion of structured RNA in bacteria [142,143], whereas 
PNPase mainly plays a role in mRNA degradation [16,48].  
Sequence alignment shows that PNPases from various kingdoms share a 
classical domain structure consisting of: two N-terminal RNase PH domains (containing 
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the PDX catalytic sites, designated PNP1 and PNP2), an α-helical domain between 
PNP1 and PNP2, and the RNA-binding domains KH (K-homology) and S1 domain 
located at the C-terminal (Figure 5.1) [13,18,19].  
 
Both RNase PH and PNPase form ring-like structure (hexameric and homotrimeric 
respectively) with a central channel in its active form. The level of structural and 
sequence similarity between the PDX domains in PNPase and RNase PH raises the 
possibility that these domains may have originated from a common ancestor (in the 
most recent common ancestor of life; MRCA) via gene duplication events [91,93].  
Previously, our primary focus has been to analyze how the three PDX domains 
(PNP1, PNP2 and RPH) have evolved in the tree of life. However, recent structural and 
phylogenetic information on these domains has made possible the examination of the 
evolutionary dynamics of their function.  One common tool that is used to examine 
functional significance of proteins over evolutionary time is to characterize the impact of 
natural selection on sequence change.  The methodology for statistically assessing 
Fig. 5.1. Schematic diagrams of PNPase (old-35) and RPH showing the various 
domains in these proteins. The domain name is given above the diagram and the 
length of the domain is given below the diagram. 
	  
	  	   130	  
patterns of natural selection in a phylogenetic context on a residue by residue basis, as 
well as on a branch by branch basis in a phylogeny are well developed [144-147]. They 
are based on corrected assessment of the ratio of nonsynonomous to synonymous 
substitutions over evolutionary time.  The null hypothesis in such studies is the situation 
where the nonsynonymous to synonymous changes are equal in abundance.  A 
statistically significant overabundance of nonsynonymous change relative to 
synonymous change is usually taken as an indication of positive natural selection.  And 
a significant lack of nonsynonymous change to synonymous change has been taken as 
evidence for negative or purifying selection by researchers. 
These approaches have been criticized on statistical grounds [148] and on the 
grounds that statistical demonstration of selection is only the first step in understanding 
natural selection on proteins.  In other words, once natural selection has been 
suggested by statistical methods it should also be tested in a functional or biochemical 
context [148,149]. 
Here, we use the well known functional and structural characteristics of the PNP 
and RPH domains to examine the validity of statistically determined measures of natural 
selection.  Several sites in PNPases have been mutagenized and the functional 
significance of those mutations has been well characterized.  In addition, sequence 
integrity is an invariable factor [148], but recent advances in structural biology show that 
secondary structure is equally important in not only determining the functionality but 
also in dictating the rates of site-specific evolution of proteins [150]. These residues 
under natural selection (positive or negative) may occur in ordered (α-helices and β-
sheets) or disordered (random coils and turns) regions [151]. However, from our 
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analyses of PNP1, PNP2 and RPH sequences from 43 eukaryotic taxa (Table 5.1), we 
can infer that the residues with dN/dS measures greater than 1 are almost entirely 
found outside of α-helices and β-sheets. Finally, through phylogenetic analysis, we have 
been able to discern the possible time course of evolution and molecular events when 
PNPase (PNP1, PNP2, KH and S1) and RPH domains might have been under positive 
natural selection among vertebrates.  
Table 5.1. Taxa used in the study 
Deuterostome   
 Mammals Primates 
  Homo 
  Pan_ 
  Papio 
  Macaca 
  Nomascus 
  Otolemur 
  Calithrix 
  Saimiri 
 Carnivora Felis 
  Canis 
  Ailuropoda 
 Rodentia Cricetulus 
  Mus 
  Rattus 
  Cavia 
  Oryctolagus 
  Sus 
  Bos 
  Equus 
  Loxodonta 
 Marsupials Monodelphis 
  Sarcophilus 
  Ornithorhy 
 Lizards/Birds Gallus 
  Taeniopygia 
  Anolis 
 Amphibia Xenopus 
 Fish Takifugu 
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  Danio 
  Oreochromis 
Other deuterostome  
  Branchiostoma 
Protostome   
 Insect Drosophila 
  Tribolium 
 Nematode C.elegans 
 Worm Brugia 
 Lower Metazoa Amphimedon 
  Trichoplax 
  Nematostella 
Plant  Arabidopsis 
  Physcomytrella 
  Selaginella 
 
5.3 Materials and Methods 
5.3.1 Sequences and Matrix construction 
PNPase and RNase PH sequences were obtained from Genbank using a 
taxonomic sampling strategy to cover the eukaryotic tree of life. Only PNPase and 
RNase PH sequences from fully sequenced and accurately annotated eukaryotic 
genomes were used. A list of the taxa used in this study is given in Table 5.1. Codon 
sequences were obtained in all cases and accession numbers for the sequences are 
given in Table 5.1. Sequences were aligned in TranslatorX [152] a program that aligns 
codons using amino acids as a guide. For the various analyses in this paper we 
generated several different phylogenetic matrices that were used in tree building and 
natural selection detection programs. The first kind of matrix we generated was a 
taxonomic based matrix with the 43 taxa we list in Table 5.1. This matrix consists of full-
length PNP sequences concatenated with RNase PH sequences for the same 43 taxa 
in a NEXUS formatted matrix. The different regions of the PNPase genes and the RPH 
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gene (Figure 5.1) were then partitioned using NEXUS commands in the NEXUS matrix. 
The root of this matrix was established using the three plant taxa (Arabidopsis, 
Selaginella and Physcomytrella) as outgroups.  
The second kind of matrix combined PNP1, PNP2 and RPH domains from all 43 
taxa used in this study. This matrix was constructed using a separate alignment 
procedure from the taxonomic-based matrix. In addition two RNase II genes (one from 
human and the other from Trichoplax) were used to root trees for this latter matrix.  
5.3.2 Phylogenetic analysis 
Phylogenetic trees were constructed using parsimony, maximum likelihood and 
Bayesian approaches [153]. The model used was a GTR with invariants rates and 
gamma distribution (estimated from the data set). 100 bootstrap replicates were 
performed when bootstrapping (either MP or ML) [154]. Bayesian analysis was 
performed using 1 million generations of simulation and the model described above. For 
the selection analyses we used a predetermined tree topology based on the well-
accepted taxonomy of the organisms in the study [155].  
5.3.3 Detecting the Statistical imprint of skewed dN/dS ratios 
For the selection analyses we used a predetermined tree topology based on the 
well-accepted taxonomy of the organisms in the study [146]. Two tests were used to 
detect statistically significant patterns of skewed dN/dS ratios. The first test determines 
the branches in the accepted phylogeny where statistically significant departure from 
neutral evolution occurs. The BREL (Branch-site Random Effects Likelihood) test in the 
HyPhy [156] package was used on the three domains for the taxon based matrices 
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(PNP1, PNP2 and RPH) separately. In addition, the BREL option was also used to 
analyze branch specific natural selection in the matrix with all three-domain sequences 
as terminals. The default settings and the accepted tree topology were used in these 
tests [157,158]. 
The second test implemented the MEME (Mixed Effects Model of Evolution) 
[159] option in DataMonkey, the web version of HyPhy [157,159]. This option uses 
mixed model approaches to detect departure from neutrality at individual codons. This 
latter test was performed individually on each of the three domains – PNP1, PNP2 and 
RPH. 
5.3.4 Mapping Sites with dN/dS Skew Onto Secondary and Tertiary Protein 
Structure 
The NIH-NCBI Structure Summary MMDB 
(http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.shtml) was used to map residues 
onto the tertiary structure of PNPase and RNasePH proteins. The CN3D software 
(http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml) was used to visualize tertiary 
structure. This program allows for the selection of residues previously determined as 
under positive natural selection using the “Select Columns” option. Once these residues 
are selected their position in the three dimensional model of the protein are marked by 
yellow “slivers”. The CN3D structures presented are for the trimeric conformation of the 
protein. 
The secondary structure of these two proteins was mapped using the RCSB-
PDB web browser (http://www.rcsb.org/pdb/home/home.do) using the “Sequence” 
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pulldown menu. This web browser produces a linear model of the proteins with regions 
corresponding to alpha helices, beta sheets and other critical secondary structures 
marked on the sequence. For obtaining both the tertiary and secondary structures of 
these proteins the human sequence was used as a guide. 
5.4 Results 
5.4.1 Phylogenetic relationships of PNP domains 
The matrix with domains as terminals yielded a tree where the different PNP 
domains are monophyletic with respect to one another (Figure 5.2). In addition, the root 
of the Bayesian domain tree indicates that PNP1, PNP2 and RPH cannot be 
determined. However, both maximum parsimony and maximum likelihood recover a tree 
wherein PNP2 and RPH are sister taxa (root at arrow in Figure 5.2), as previously 
reported by Leszczyniecka et al., (2004) [91]. This rooting indicates that the PNP1 
domain appeared first in the genomes of the common ancestor of all life, and that PNP2 
and RPH arose as the result of subsequent duplication events. This rooting lacked 
robustness since the out-groups (human and trichoplax RNase II) are quite distant from 
the in-group domains.  Large out-group distances can result in random rooting [160] on 
the in-group and this may explain why the Bayesian analysis fails to recover a more 
resolved root for the domain tree.  
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5.4.2 Branch Specific Skew in dN/dS ratios 
The BREL test in HyPhy detected several branches in the backbone of the 
vertebrate phylogeny leading to mammals that show significant departure from a dN/dS 
ratio of 1.0 (Figure 5.3). Specifically all of the seven branches in the tree in Figure 5.3, 
leading to mammals from the common ancestor of Branchiostoma and true vertebrates 
show a shift in intensity of this skew. Of these seven branches, three are impacted by 
skewed ratios in PNP1, two in PNP2 and three in RPH. There are only two other 
Fig. 5.2. Bayesian phylogenetic tree showing the relationship of the three major 
domains (PNP1, PNP2 and RPH) examined in this study. 
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regions of the tree where two of the genes exhibit skew of this ratio. One region involves 
the lineage leading to protostomes (i.e. insects and nematodes), and the other, the 
lineage leading to Bos and Sus (bovids and pigs). These results suggest a major shift in 
sequence dynamics and subsequent stabilization of the evolution of these protein 
domains as vertebrates, fish and mammals evolved. 
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5.4.3 General Site-specific Skew in dN/dS ratios in PNP domains 
The MEME analyses of PNP1, PNP2, RPH and the KH domains (Figure 5.4A) 
indicate that the sites experiencing positive dN/dS skew are generally outside of α-
helices and β-sheets (Figure 5.4B). Surprisingly, RPH appears to have twice as many 
sites that are positively skewed compared to PNP1 or PNP2 (Figure 5.4B).  
Fig. 5.3. Tree of animal life using plants as an outgroup showing which 
branches on the tree have experienced positive dN/dS skew. The domains that 
are under selection are shown in colors and the nodes where positive skew exists 
are colored accordingly for the different domains. The dotted lined box indicate the 
region of the backbone in the tree leading from primitive vertebrates to mammals 
where positive dN/dS skew has occurred in the four domain regions we examined. 
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Fig. 5.4. Site-specific positive dN/dS skew in the three PNP domains 
(PNP1, PNP2 and RPH) and the KH and S1 domain. (A) The cartoons 
show the location of α-helices (green), β-sheets (tan), and the S1 region 
(yellow). Also indicated are the specific locations of sites that have skewed 
dN/dS ratios (red lines). (B) Bar chart showing the number of sites in beta-
sheets and alpha helices under positive skewed dN/dS. The green bars 
show the number of sites that are either not in sheets and helices or on the 
very edge of a sheet or helix. The red bars show the number of sites that 
have positive skewed dN/dS that are squarely within alpha helices. There 
were no sites positive skew found squarely in beta sheets. 	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All of the RPH sites that show positive skew are in the N-terminus of the protein. In 
contrast, the sites with positive dN/dS ratios in the PNP domains are oftentimes in the 
C-terminus, which might impact how the helices and β-sheets in the domains make 
turns. The S1 domain consists primarily of β-sheets with four skewed sites at the C-
terminus, outside of the sheets (Figure 5.4). In total, 17 sites in all of these domains with 
positively skewed dN/dS ratios are either outside of sheets and helices or in the first 
residue of a sheet or helix. Only three sites with positive skew lie squarely within alpha 
helices, and none within the beta sheets. Secondary structure plots indicating sites 
experiencing positive dN/dS skew in PNP1, PNP2, KH/S1 and RNase PH are provided 
in Figures 5.5 and 5.6. 
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 Fig. 5.5. Secondary structure plot indicating sites under positive 
selection in PNP1, PNP2 and KH/S1 (sites highlighted as green 
circles). 
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5.4.4 Correlating skewed dN/dS with structural variants 
The locations of residues with significant dN/dS>1.0, relative to the protein’s 
three-dimensional structure were visualized through the use of the CN3D software. 
Most of the skewed sites (yellow linings) in the PNP1, PNP2, and KH/S1 domains of 
PNPase (Figure 5.7), as well RNase PH (Figure 5.8) are either outside or at the edges 
of ordered secondary structures.   
Fig. 5.6. Secondary structure plot indicating sites under positive selection in RNase 
PH (sites highlighted as green circles). 
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Fig. 5.7. 3-D visualization of positively selected sites in PNP1, PNP2 and KH/S1 
using the CN3D software. The upper left panel shows the three dimensional crystal 
structure of the human PNPaseold-35 protein. Each of the subsequent panels shows 
the position of sites under natural selection (yellow slivers). Helices that have sites in 
the middle or on the edge are visualized with this software as well as the position of 
sites that are not in helices or sheets. 
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Next we compared the positions of residues that cause known structural variation 
via mutagenesis with their dN/dS ratios.  Because the functional significance of the 
mutagenized residues is known this comparison allows us to examine possible 
correlations of significant dN/dS values with function.  Since most of the mutagenized 
sites were chosen to disrupt function, we do not expect a direct correlation of 
significantly skewed dN/dS ratios with mutagenized site.  In fact, we hypothesize that 
mutagenized sites disrupting function should be under intense purifying selection, and 
have no significant dN/dS ratios.  For the most part this is what we observe, and in 
addition, it appears that many of the sites chosen for mutagenesis are embedded in 
Fig. 5.8. 3-D visualization of positively selected sites in RNasePH using the 
CN3D software. The left panel shows the three dimensional structure of the human 
RNase PH protein. The panel on the right shows the position of sites under natural 
selection (yellow slivers). Helices that have sites in the middle or on the edge are 
visualized with this software as well as the position of sites that are not in helices or 
sheets. 
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regions of these domains that show dN/dS ratios that are not significantly different from 
0.0 (an indication of strong negative or purifying selection).  There are some exceptions. 
PNPase domains:  Table 5.2 lists the residues in PNP domains that have been 
mutagenized and the functional significance of the variation along with the sites 
detected in this study with statistically significant dN/dS ratios > 1.0.  The only extreme 
overlap of positively skewed dN/dS ratio with a site mutagenized that alters function is 
S483 a dN/dS > 1.0 site which is a binding site for Citrate D 670 located near the active 
site.  This significant dN/dS site is right next to the S484 mutagenesis site, which 
abrogates polymerization and degradation activities of hPNPase.  The juxtaposition of 
these two sites is interesting and it could be hypothesized that the S483 dN/dS site 
might have been involved in the evolution of this function.  P519 a site that has a dN/dS 
ratio > 1.0 is also the position of a somatic mutation (P519T) found in hPNPase that was 
identified through the COSMIC (http://cancer.sanger.ac.uk/cosmic) database.  This site 
is not observed as a mutated site in human populations with any significant frequency, 
but it could be hypothesized that this site is important for a derived hPNPase function in 
normal human or primate tissues and this function may be disrupted after the mutation 
found in a cancer patient (P519T). This might be a very interesting residue to work with 
in the future and would have to be validated in future in vitro experiments. Since this 
residue is solvent exposed, it could be a site required for interaction with other proteins, 
a premise that would also need further verification.   
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Table 5.2.  PNP domains comparison of significant dN/dS with mutagenized sites. 
Domain Conserved residues 
dN/dS 
residues 
Function 
affected Ref. 
PNP1 or 2 wt  pol ++ / deg ++ [30,44] 
PNP1 D135G 14 X 12 pol - / deg - [30,44] 
PNP1 n S211 ?  
PNP1 n V247 ?  
PNP1 n T266 ?  
PNP1 n V268 ?  
PNP2 n F377 ?  
PNP2 Q387R 9 x 16 
Blocks trimer 
formation, 
mtRNA 
import, mt 
translation 
 
[161] 
PNP2 R445E 19 XX 12 pol +++ / deg + [30,44] 
PNP2 R446E 18 XX 11 pol +++ /deg + [30,44] 
PNP2 E475G 17 X 7 Blocks trimer 
formation 
[108] 
PNP2 S484A S483 pol - deg - [30,44] 
PNP2 D538A 15 X 5 X 26 pol + /deg + [30,44] 
PNP2 D544G 15 X 5 X 26 pol +++ / deg + [30,44] 
PNP2 n P519 ? 
Somatic mutation 
(COSMIC database)  
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PNP2 n N590 ?  
 
Red lettering = mutagenized sites and green lettering positively skewed dN/dS sites.  
Green shading = two codons adjacent to each other R445 and R446.  Blue shading 
marks two codons within six codons of each other D538 and D544.  The notation for 
dN/dS for conserved mutagenized sites is nXm, where X indicates the position of a 
mutagenized codon and n indicates the number of residues toward the amino end of the 
protein that have dN/dS = 0.0, and m indicates the number of residues toward the 
carboxy end of the protein that have dN/dS = 0.0 
 
RPH domain:  The sites with dN/dS>1.0 at the amino terminal of this domain are 
interspersed with several sites that have been altered by mutagenesis (Table 5.3).  The 
first 22 or so residues appear to be very important in maintaining the structural integrity 
of the domain and both mutagenized and skewed dN/dS sites exist here.  This result 
could point to the importance of this region in maintaining the structural integrity of the 
domain.  The remainder of the residues in this domain behaves, as we would predict.  
Any mutagenized residue appears to be embedded in long stretches of sites with dN/dS 
ratios not significantly different from 0.0, indicating a strong tendency toward 
conservation of sequences and of function.  Any sites showing positively skewed dN/dS 
> 1.0 are outside of these highly conserved regions. 
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Table 5.3.  RPH Comparison of significant dN/dS with mutagenized sites.  
Conserved 
residues 
dN/dS 
residues Function Ref. 
R12 Y11 structural [162] 
D14 D14 structural [162] 
R16 G15 structural [162] 
R22 5 X 5 structural [162] 
n G36 ?  
n A38 ?  
n T45 ?  
R61 11 X 10 RNA-binding (RNA entry site) [162,163] 
A62 12 X 9 RNA-binding (RNA entry site) [162,163] 
n C73 ?  
n F80 ?  
n E84 ?  
R93 
3 XX 3 X 12 
RNA-binding 
(RNA exit site) [162,163] 
K94 
3 XX 3 X 12 
RNA-binding 
(RNA entry site) [162,163] 
E97 3 XX 3 X 12 RNA-binding [162] 
D130 
22 X 3 X 40 
phosphate-
binding [162] 
T133 
22 X 3 X 40 
phosphate-
binding [162] 
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D171 40 X 4 XX 31 catalytic [162] 
E176 40 X 4 XX 31 catalytic [162] 
E177 40 X 4 XX 31 catalytic [162] 
 
Red lettering = mutagenized sites and green lettering positively skewed dN/dS sites.  
Green shading two codons adjacent to each other. Different shading indicates sites that 
are in close adjacency to one another.  The notation for dN/dS for conserved 
mutagenized sites is nXm, where X indicates the position of a mutagenized codon and n 
indicates the number of residues toward the amino end of the protein that have dN/dS = 
0.0, and m indicates the number of residues toward the carboxy end of the protein that 
have dN/dS = 0.0 
 
KH domain:  Two residues in the KH domain identified as having positively 
skewed dN/dS ratios, T635 and I667, are highly conserved [31], and located around the 
pore of the trimeric protein near residue G622 (Table 5.4) which has been shown to be 
important for RNA binding [31].  Again these may be positions that show strong positive 
selection because of recent acquisition of function.  In addition, two other sites might be 
involved in trimer formation - S211 and A633. It could be that these are important for 
trimer formation or RNA binding as suggested by their location and evolutionary 
conservation, but this again would need to be tested by extensive mutation analysis and 
biochemical assays.         
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Table 5.4. KH domain comparison of significant dN/dS with mutagenized sites.  
Domain Conserved residues 
dN/dS 
residues Function Ref. 
KH/S1 G622D 10 X 10 RNA binding lost [31] 
KH/S1 n A633 ? 
KH/S1 n T635 pore of the trimeric protein 
KH/S1 n I667 pore of the trimeric protein 
 
Red lettering = mutagenized sites and green lettering positively skewed dN/dS sites. 
The notation for dN/dS for conserved mutagenized sites is nXm, where X indicates the 
position of a mutagenized codon and n indicates the number of residues toward the 
amino end of the protein that have dN/dS = 0.0, and m indicates the number of residues 
toward the carboxy end of the protein that have dN/dS = 0.0 
 
5.5 Discussion 
There are two evolutionarily conserved members of the PDX family of proteins: 
RNase PH and PNPase. The RNase PH protein is the simplest 3’→5’ phosphorolytic 
exoribonuclease which can be considered as a prototype of the PDX family of proteins 
[4,14]. Within PNPase are the catalytic domains PNP1 and PNP2, which share 
significant sequence similarity with RNase PH. The evolutionary origin of RNase PH can 
be traced in a straightforward manner because it exists in bacteria, and has orthologues 
in Archaea and Eukarya. Its ubiquitous phylogenetic distribution exemplifies the 
functional importance of this ribonuclease. In contrast, PNPase is absent in all Archaea 
and single cell eukaryotes such as yeast [13,91,93]. The prevalent phylogenetic 
distribution of these proteins and sequence similarity between them raises the 
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possibility that the PDX domains of PNPase (PNP1 and PNP2) and RNase PH arose 
via gene duplication events from a common origin (i.e. the most recent common 
ancestor; MRCA) [91,93].  The current study attempts to address where in the 
phylogenetic history did major sequence changes appear that might have shaped the 
important functions of these domains.  
Domain evolution in PNPases: Phylogenetic analysis performed in this study, using 
sequences of RNase PH, PNP1 and PNP2 domains from 43 eukaryotic taxa, confirms a 
previous finding that PNP2 and RPH are more closely related to each other (i.e. sister 
taxa), with PNP1 having diverged from the PDX domain family earlier in evolution 
[91,93]. The rooting of parsimony and likelihood trees specifies PNP1 as the domain 
that appeared in the genomes of the Most Recent Common Ancestor (MRCA) of life. 
This is consistent with the PNP1 “first” hypothesis being the most parsimonious and 
likely scenario. This being the case, it seems safe to assume that PNP2 and RNase PH 
arose as a result of duplication events. If RNase PH emerged only during later stages of 
evolution, it is important that we explain the presence of its orthologues in all kingdoms 
of life, while PNPase is absent in all Archaea and a number of other organisms. There 
are two likely explanations. First, the terminally duplicated RNase PH domain could 
have been transferred to Archaea by horizontal gene transfer (HGT) via the common 
Eukaryote ancestor. Second, the full-length PNPase might have been lost in the 
Archaeal lineage. The “node height test” predicted that the lineage extinction of PNPase 
in Archaea is the more acceptable sequence of events, which occurred during the 
evolution of these domains [91,164]. In any case, the series of events or the kinds of 
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selective pressure that may have factored in this evolutionary process are still under 
speculation.  
Branch Specific Sequence Skew:  For PNPase and RNase PH, a deeper 
understanding of the process of sequence change during their evolution, may translate 
to better insights regarding the proteins’ conserved (and evolved) functionalities. Using 
the Branch-site Random Effects Likelihood (BREL) and Mixed Effects Model of 
Evolution (MEME) analytical tools, we were able to identify previously unknown branch- 
and site-specific departures from dN/dS=1.0 related to the PNP1, PNP2, KH, S1 and 
RPH domains [158,159].  When a codon has a dN/dS ratio that is statistically 
significantly greater than 1.0 we call this positive skew.  BREL analyses led to the 
detection of lineage specific positive skew relating to all the five domains during 
vertebrate evolution. The advantage of this approach is its ability to infer episodic skew 
events on branches in a phylogeny. Moreover, this tool helped us identify the three 
branches of the phylogeny of animals exhibiting a significant positive skew in dN/dS. 
The first branch is the lineage leading to Protostomes (the lineage that is sister to the 
large clade that vertebrates belong to) where both PNP1 and KH/S1 show positive skew 
once. The second region comprises seven branches in the vertebrate phylogenetic tree 
leading to mammals from the common ancestor of Branchiostoma, with all of them 
exhibiting significant positive skew in one or more of the domains of PNPase and 
RNasePH.  The third branch is the lineage leading to Bovids where both PNP2 and 
RPH show positive skew once. As pointed out earlier, the inference we can draw from 
these findings is that all four protein domains PNP1, PNP2, RPH and KH/S1 
experienced positive skew during sequence evolution leading to the vertebrates, after 
	  	   153	  
which the analysis suggests stabilization of the domains leading to higher mammals. 
While we cannot at this point in time claim that natural selection was at work in molding 
these domains in the common ancestor of the vertebrates, we can point to the fact that 
some highly skewed sequence change occurred in the lineage leading to vertebrates. 
Domain Region Specific Sequence Skew:  Results of MEME analyses indicate that 
the sites with positive dN/dS skew in the PNP1, PNP2 and RPH domains are mostly 
located outside α-helices and β-sheets or in other words are in disordered regions of the 
domains. In the N-terminal region of the PNP1 protein domain, only two out of ten sites 
showing skew are located within β-sheets. These observations are actually consistent 
with recent reports that amino acids located in the disordered regions (e.g., random 
coils and turns) of protein secondary structure are more likely to be under positive 
selective pressure, relative to residues in the more structurally conserved regions like α-
helices and β-sheets [150,151]. More specifically, Nilsson and colleagues [150], upon 
their examination of the molecular evolution of 3746 genes across 64 strains of budding 
yeast (S. cerevisiae, S. paradoxus), concluded that there is a significantly higher degree 
of positive Darwinian selection in intrinsically disordered regions compared to alpha 
helix, beta sheet or tertiary structures.  
In their analysis of 26 protein families, Brown and co-workers concluded that 
disordered regions in proteins generally have faster rates of evolution [165]. These 
observations are possibly related to the roles disordered regions play in the protein’s 
functionality. As Mittag et al explained [166], higher mutation rates in disordered regions 
may have been allowed during evolution because sequential modifications within these 
regions did not pose severe consequences on protein stability and functionalities. 
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Moreover, the disordered regions provide protein flexibility necessary for recognition of 
other molecules (such as other proteins and RNAs). This is especially applicable for 
proteins such as PNPase and RNase PH, whose target molecules can have a varying 
range of secondary and tertiary structures. For PNPase and RNase PH, the need to 
adapt to its target molecules is very crucial since the target molecules themselves are 
evolving (i.e., mutating) as they adapt to new environment and species physiology. 
Another interesting observation in our study is the higher incidence of dN/dS 
positive skew in the N-terminus of RPH compared to those of the PNP1 and PNP2. In 
the C-termini of the domains, the opposite was evident. The N- and C-termini of proteins 
encompass important binding motifs, and it is possible that the termini regions of these 
domains, as they diverged during evolution, required different structural modifications 
for the different molecules (e.g., helicases or other ribonucleases) they interact with. 
Overall, RPH has twice as many positively skewed sites as PNP1 or PNP2. In other 
words, RPH has undergone more changes at the molecular level than either PNPase 
domain. One possible interpretation is that RPH is evolutionarily more malleable than 
the PNPase domains. This perhaps explains the emergence of RPH orthologues in all 
kingdoms of life, after it had diverged from the linked PNP domains early on during 
organismal evolution [91,93]. 
Positive skew in codons was also detected in the structurally more complex KH 
domain (at numerous positions in α-helices), as well as the S1 domain (at four positions 
in the β-sheets at the C-terminus). These events were likely structural refinements that 
subsequently aided PNPases in higher organisms as it necessitated them binding to 
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newer mRNA and miRNA species. A prime example of this is the human PNPase which 
has high specificity for binding and degrading c-myc mRNA and miR-221 [48,49,67,93].  
Correlating positive dN/dS skew with mutagenized sites:  There is a direct 
correlation between sites chosen for mutagenesis and the loss of function of the 
PNPase and RNasePH proteins and an inverse correlation of these sites with positive 
dN/dS skew.  In general, sites that are important for the function of these proteins as 
determined by mutagenesis studies appear to be embedded in regions of the protein 
with dN/dS values that are not significantly different from 0.0.  This result suggests that 
sites adjacent to those currently chosen for mutagenesis studies might also be 
appropriate candidates for mutagenesis to study the function of these proteins.  There 
are two major exceptions to this general trend.  The first concerns a region of the PNP2 
domain where two serine (S) residues are adjacent to each other.  One serine (S484) 
has been mutagenized and has been shown to be near a binding site for Citrate D 670 
located near the active site of the protein.  A site directly adjacent to site S484 (S483) 
has positive sequence skew, indicating that this region of PNP2 has some interesting 
sequence evolution dynamics involved with it.  The second departure from the general 
inverse relationship of positive skew with mutagenized sites is at the amino terminus of 
the RNasePH domain, where a six amino acid stretch (Y11, R12, D14, G15, R16) has 
three residues important for structure of the protein and three residues with positive 
dN/dS skew.   
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In summary, we present a study that analyzed the molecular events, which have 
occurred during the course of evolution of two important RNA degrading enzymes. We 
attempted to explain why some regions of the proteins are biased towards positive 
dN/dS skew. We have exercised caution in not calling these codons with positive skew 
as sites under positive natural selection and in calling codons chosen for mutagenesis 
as sites under purifying selection.  We do however suggest that the sites we have 
identified in this study as skewed are sites that are good candidates for examining the 
dynamics of the activity of these proteins.  We also suggest that previous choice of sites 
for mutagenesis chosen on the basis of extreme conservation, have settled on codons 
in regions where surrounding codons have extremely low dN/dS ratios that are for the 
most part not significantly different from 0.0.  This result suggests that sites adjacent to 
those currently in use for mutagenesis studies could be used to expand the repertoire of 
tools for studying the functionality of these proteins. 
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CHAPTER SIX 
 
 
 
 
General Discussion 
 
Human polynucleotide phosphorylase (hPNPaseold-35) is an evolutionarily 
conserved 3’-5’ exoribonuclease [13,91,93]. It has been implicated to play a role in 
numerous cellular functions, like growth arrest, apoptosis, senescence associated 
degenerative diseases, hearing loss, inflammation, mtRNA import, maintenance of 
mitochondrial homeostasis, mtRNA processing and decay. Most of its functions in the 
mitochondria are associated with cellular maintenance and routine RNA processing 
activities [13,67,93]. As an exoribonuclease in the cytoplasm is has been found to 
degrade c-myc mRNA and miR-221 [48,49], which ultimately leads to apoptosis of 
cancer cells. Apart from these two mRNA and miRNA species not much is known about 
the degradation targets of hPNPaseold-35. These functions of hPNPaseold-35 have been 
extensively described in Chapter 1. 
The overall aim of this project was to identify degradation targets of hPNPaseold-
35 other than c-myc and miR-221 and also to further understand the role of hPNPaseold-
35 in the maintenance of cellular homeostasis and this premise has been extensively 
dealt with in Chapters 2 and 3. Identification of hPNPaseold-35 targets would help in not 
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only furthering our understanding of this protein, but may also provide novel therapeutic 
targets for treatment of cancer and other hPNPaseold-35-associated diseases. Another 
aspect of this project was to evaluate the evolutionary history of hPNPaseold-35 in 
comparison with another RNA degrading enzyme RNasePH, with special focus on the 
prediction of functionally important residues under natural selection, mutating which 
would hamper the enzymatic activity or RNA binding ability of these proteins. In the 
current work (Figure 6.1), we were able to (i) identify hPNPaseold-35- “directly” and 
“indirectly” regulated genes in two different overlapping analyses; (ii) demonstrate that 
hPNPaseold-35 stable knockdown causes global changes in mitochondrial respiratory 
complex and associated genes; (iii) show that hPNPaseold-35 overexpression causes 
global changes in cell cycle associated genes; (iv) identify amino acid sites under 
positive natural selection in hPNPaseold-35 which could be of potential importance in 
mediating its catalytic activity and RNA binding ability.    
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In order to identify direct degradation targets of hPNPaseold-35, we performed 
microarray analysis on cell lines in which hPNPaseold-35 was overexpressed and 
knocked down. In Chapter 2 we used melanoma as a model system to answer these 
questions. We were able to identify a number of candidate genes through our 
overlapping analysis which could be potential direct or indirect targets of hPNPaseold-35 
and were also able to validate the already known involvement of hPNPaseold-35 in 
biological processes like mitochondrial respiration and cell cycle arrest with the help of 
Fig. 6.1. Flow chart depicting overall aim of project: to identify degradation targets of 
hPNPaseold-35.  
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pathway analyses tools in IPA (Ingenuity Pathway Analysis). We identified 77 potential 
direct targets and validated certain genes like CENPE and MKI67, which are important 
for cellular growth and proliferation as being repressed by hPNPaseold-35 by transient 
knockdown and overexpression of hPNPaseold-35. Future experiments would involve 
verifying the exact mechanism by which hPNPaseold-35 regulates these genes. In vitro 
RNA degradation assays would be able to validate if hPNPaseold-35 actually degrades 
these transcripts. Other mechanisms of regulation could be more complex and may 
involve hPNPaseold-35 –regulated miRNA species targeting genes (like certain 
transcription factors), which in turn control the expression of the aforementioned 
identified transcripts. To pursue this particular avenue, an analysis of the promoter 
regions of the identified direct targets would provide precise knowledge of the 
transcription factor (TF) binding elements. If the regulation of the identified targets by a 
specific TF has not been reported yet, reporter based assays can be performed to 
validate regulation. Finally, a search using the numerous miRNA databases (e.g. 
miRBase or TargetScan) can help identify any predicted or validated miRNAs that target 
our TF of interest, and even further through RNA degradation assays we can validate if 
hPNPaseold-35 regulates that particular miRNA. A similar approach could be used to 
validate the mechanism of hPNPaseold-35-regulation of the potential indirect targets 
identified like VGF, RNF128 and MCAM, which could probably be regulated by miRNAs 
targeted by hPNPaseold-35. In this case we would need to identify miRNA binding sites in 
these transcripts by scanning the aforementioned miRNA prediction databases, then 
functionally prove that the specific miRNA targets the specific gene by overexpression 
or knockdown of the miRNA and finally investigate if hPNPaseold-35 regulates it. Of 
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particular interest here is the gene MCAM, which is a cell surface receptor associated 
with poor prognosis of melanoma and other cancers [167,168]. hPNPaseold-35 
knockdown causes the downregulation of this gene, identifying the mechanism of 
hPNPaseold-35-regulation of MCAM (probably via miRNA) may provide valuable 
therapeutic opportunities for melanoma treatment [169]. In the same context, VGF 
(usually only expressed in nerve cells or neuroendocrine cells) could be promising 
candidate too, which is upregulated in lung cancer [170].         
In Chapter 3, we extended to identify possible hPNPaseold-35 induced or 
repressed genes by performing a similar microarray experiment in HeLa cells following 
hPNPaseold-35 overexpression using a doxycycline-inducible expression vector. The 
purpose of this additional microarray was to gain perspective relating to hPNPaseold-35 
functions in a system other than melanoma and eventually, comparison of two 
hPNPaseold-35 datasets in two different cell lines may provide a more global perspective 
of hPNPaseold-35 associated gene expression changes. First, in order to identify 
hPNPaseold-35 induced or repressed genes, we performed a similar overlapping screen 
that we performed in Chapter 2. We used the same melanoma hPNPaseold-35 
knockdown dataset we used in Chapter 2, but this time we overlapped it with our HeLa 
hPNPaseold-35 dataset rather than with the melanoma. In this analysis we identified 28 
repressed and 62 hPNPaseold-35 -induced transcripts. Of special interest here was the 
identification of two hPNPaseold-35 -repressed genes CENPE and MKI67, which we also 
identified in our melanoma screen. Future experiments would be required to confirm 
their direct degradation by hPNPaseold-35 or whether they are downstream/indirect 
effects of the downregulation of a key TF like c-myc, which can be validated by myc-
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knockdown experiments. Another interesting hPNPaseold-35 –repressed gene identified 
here was CENPA, which was downregulated in three melanoma cell lines upon Ad. 
hPNPaseold-35 infection, but levels of which did not change significantly in an  
immortalized normal human melanocyte cell line FM516 in preliminary experiments. 
CENPA is associated with poor prognosis in breast cancer [134], and thus could prove 
to be a potential therapeutic target once we could figure out the mechanism of 
hPNPaseold-35 –regulation of this gene, which seems to be indirect as levels of CENPA 
did not change in immortalized normal cells. We were also able to identify significant 
similar correlations of hPNPaseold-35 expression with a number of the identified induced 
and repressed genes in four TCGA datasets we analyzed: colon adenocarcinoma 
(COAD), skin cutaneous melanoma (SKCM), ovarian serous cyst adenocarcinoma 
(OV), and prostate adenocarcinoma (PRAD). Some of the interesting candidates in this 
category were DUSP1, ADARB1 and EMR2, all of which negatively correlate with 
hPNPaseold-35 expression and are upregulated in different cancers [136-140]. As 
explained earlier as in the case of CENPE, MKI67, VGF, MCAM and CENPA, once the 
mechanistic details of the regulation of these genes by hPNPaseold-35 are identified, they 
could lead to the discovery of promising therapeutic interventions.                  
We also compared the gene expression profiles of melanoma and HeLa cells in 
which hPNPaseold-35 was overexpressed, and as detailed in Chapter 3, apart from the 
fact that almost all the 105 common dysregulated genes identified belonged to cell 
cycle-associated gene ontology categories, some of them were also identified as 
possible transcriptional targets of c-myc. Therefore, although this analysis provided us 
with a gene expression signature of hPNPaseold-35 induced growth arrest, unless we can 
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prove otherwise (through RNA degradation assays), it would be difficult to say at this 
point whether they are direct targets of hPNPaseold-35 or dysregulated due to changes in 
c-myc levels. In order to pursue this avenue further, validation of these genes in a myc-
null background would be helpful, which would confirm whether dysregulation of these 
genes is caused by hPNPaseold-35 or c-myc.  
An alternative approach to validate the directly degraded targets of hPNPaseold-35 
identified in Chapters 2 and 3 would be to compare the 3’UTR sequence or secondary 
structure of c-myc (a direct degradation target of hPNPaseold-35) with the 3’UTR of these 
transcripts and recognize any common elements between them. This may also shed 
some light on the conundrum of what is/are the specificity element/s that allows 
recognition and subsequent degradation by hPNPaseold-35, a premise dealt with in 
Chapter 4. Also, since Ad.hPNPaseold-35 infection causes growth arrest of cancer cells 
resulting from degradation of c-myc mRNA with an intact 3’UTR, rescue experiments 
involving 3’UTR deletion mutants of c-myc may also help to delineate the region which 
may be required for hPNPaseold-35 recognition and degradation.  
In Chapter 5, we set out to identify the residues under natural selection in the 
different domains of hPNPaseold-35 (PNP1, PNP2, KH and S1) and another closely 
related exoribonuclease RNasePH that may be important for their enzymatic activity or 
RNA binding ability. The other purpose behind this was that maybe such an 
evolutionary analysis would help us identify exactly where in evolutionary history did or 
did not hPNPaseold-35 acquire any specificities towards the recognition of certain mRNA 
species (like c-myc) versus others. The results provided in Chapter 5 offer in depth 
insights into the sequence evolution of hPNPaseold-35 in the vertebrate lineage leading to 
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mammals. The residues under positive selection that we identified (extensively 
described in Chapter 5) could or could not be involved in the trimer formation, 
degradative or binding activities of hPNPaseold-35 and RNasePH. Future work involving 
mutation analyses of these sites followed by functional RNA degradation or binding 
assays would confirm the importance of these residues in those functions. The eventual 
importance of this work lies in understanding the biochemical importance of these 
residues, information that provide useful in treating disease states where these may be 
mutated or inactivated.  
Throughout the course of this dissertation I have tried to explore and understand 
the functional implications of hPNPaseold-35 (Figure 6.1). Although our studies have led 
to numerous conclusions as detailed in Chapters 2-5, there still remain a number of 
unanswered questions that have been discussed in the current chapter. Also, a lot 
remains unanswered regarding the biological consequences of hPNPase in normal 
versus cancer cells, and animal models with either conditional overexpression or 
knockdown of hPNPase will be extremely useful. These models will prove helpful in 
understanding the various physiological processes hPNPase is a part of, like mtRNA 
import, and will also facilitate studies relating to viral infection, mitochondrial dysfunction 
and aging allowing the future development of suitable therapeutics.   
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